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INTRODUCTION  
1. Grasses and allergy  
Grass pollen allergens are the most important causes of hay fever and allergic asthma during 
summer in cool temperate climates. About 25% of the population is affected by grass pollen 
mediated type I allergy. Symptoms can range from rhinitis, conjunctivitis, hay fever, asthma, 
urticaria, chronic eczema up to severe, life-threatening anaphylactic reactions 1. The 
underlying key pathomechanism of the allergic disease is the production of IgE antibodies, 
which bind with high affinity to the IgE-specific receptor FcεRI on effector cells like mast 
cells and basophils. Upon exposure to the respective allergen, cross-linking of the IgE and 
FcεRI occurs which leads to effector cell degranulation resulting in the release of preformed 
mediators such as histamines, prostaglandins, tryptase and heparin. These mediators 
collectively cause increased vascular permeability, vasodilation, contraction of bronchial and 
visceral smooth muscle and local inflammation. The reaction starts within minutes after 
allergen exposure and is referred to as immediate hypersensitivity. In addition, the release of 
cytokines and chemotactic factors is essential for the recruitment and activation of further 
inflammatory cells involved in the development of a late asthmatic response, which will be 
described in chapter 2. 
Among the most abundant airborne grass pollen allergen sources are meadow grasses such as 
timothy grass (Phleum pratense), orchard grass (Dactylus glomerata) and meadow foxtail 
(Alopecurus pratensis), each of them belonging to the Poaceae family 2. With very few 
exceptions, all grass pollen types show a very high degree of crossreactivity 3.  In this aspect, 
crossreactive grass pollen antigens of different species have been classified in groups, e.g. 
group 1, 2, 3 … allergens 4.  
The most complete set of allergens has so far been isolated and cloned from timothy grass 
pollen (Phleum pratense). Members of group 1 and 5 allergens appear to be the clinically 
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most relevant with an IgE reactivity of  65-85% of grass-pollen sensitized patients tested 5. 
Group 5 allergens from at least seven species of the Pooideae subfamily have been identified 
so far, whereby Phl p 5 is one of the most allergenic members. Phl p 5 has been localized in 
the cytoplasm of the pollen grain and the surface of the exine 6. It exists in two isoforms, i.e. 
Phl p 5a and Phl p 5b with molecular weights of 33 and 29 kD 7. 
The availability of grass pollen allergens depends on the allergen release from the pollen grain 
which primarily occurs under humid conditions. When the pollen grain comes into contact 
with the oral, nasal or conjunctival mucosa, it bursts under osmotic shock and releases 
allergens by expulsion of cytoplasmic fragments or parts of the pollen wall. 
However, as pollen grains are too large (approximately 10 µm in diameter) to penetrate the 
lower airways, they release allergen-containing starch granules (SG) 8. Once expulsed from 
pollen, these microparticles (< 5 µm) can create inhalable allergenic aerosols capable of 
triggering an early asthmatic response and are implicated in thunderstorm-associated asthma 
9
. In thunderstorms, strong downdrafts and outflows cause the pollens to entrain into the cloud 
base where pollen rupture is enhanced. Respirablesized pollen debris are subsequently 
transported to the ground level and are distributed by outflows ahead of the rain 10-12. 
In addition, the pollen grain itself releases proinflammatory mediators such as eicosanoids, 
which act as chemoattractants and can activate inflammatory cells present in the upper part of 
mucous membranes. Pollen associated lipid mediators (PALMs) are known to resemble 
leukotrienes and prostaglandins in function and thereby activate innate immune cells like 
neutrophils and eosinophils, shifting the immune response into a Th2-biased direction 13.  
The prevalence of allergic airway disease is furthermore linked to the increasing air pollution, 
which implicates the emission of volatile organic compounds. With the emission of ozone and 
particles in suspension, including the so called diesel-exhaust particles (DEPs), irritative 
problems with the airways occur. Via physical contact, DEPs can cause pollen rupture which 
leads to the release of paucimicronic particles. By their absorptive capacity and small size (< 
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0.1 µm-10 µm), DEPs can easily transport the allergenic particles and facilitate their 
penetration of the human airways 14. 
In sum, many factors influence the likelihood of developing clinically significant sensitization 
to allergens. This might in atopic patients only be explained by the inherited predisposition 
for allergies. There is, however, agreement today that also the type of allergen, the allergen 
concentration and whether exposure occurs together with environmental conditions and/or 
adjuvant agents which enhance the sensitization process. 
2. Allergic asthma  
Allergic asthma is a chronic inflammatory airway disease, characterized by airway 
inflammation, persistent airway hyperresponsiveness (AHR) and intermittent, reversible 
airways obstruction 15. An estimated 300 million people worldwide suffer from asthma, 
whereas 70% of these patients have allergies. The prevalence of allergic airway disease is 
rapidly increasing world-wide in all age groups; in many countries it reaches over 30% in 
children and more than 10% in adults 16, 17. In many cases asthma is associated with the 
genetic predisposition to generate type I hypersensitivity against otherwise harmless common 
environmental antigens.  
However, the predominant role of allergens in the course of asthma is questioned by the fact 
that suppression of symptoms, which occur most frequently already in childhood, have no 
influence on the outcoming of asthma later in life 18.  
Dendritic cells are known to play a crucial role in the initiation of asthma by regulating early 
inflammatory events at epithelial surfaces. Particularly children in the first years of life do not 
exhibit yet airway dendritic cells (ADC) in the absence of inflammation. However, the chance 
of a respiratory virus infection which induces inflammation and subsequent ADC maturation 
with a preferential bias towards a Th2 immune response is high. In consequence, respiratory 
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viruses  or other components of the inhaled environment predispose to allergic sensitization 19, 
20
.  
Antigen inhalation of sensitized atopic patients with asthma results in an acute early asthmatic 
response (EAR) which develops immediately after challenge and reaches a maximal 
bronchoconstriction between 15 and 30 min resolving within 1-3 hrs 21. EAR or type I 
immediate hypersensitivity (as described above), reflects the secretion of mediators at the 
affected site. Among them are histamines, prostaglandins and leukotrienes, which act via 
activation of different G-protein coupled receptors and thereby augment many features of 
asthma, like airway hyperresponsiveness, eosinophilia and mucus hypersecretion 22.  Th2 
associated cytokines IL-4 and IL-13 act together with leukotrienes to worsen the features of 
asthma. IL-4 is on the one hand essential for the activation and function of B cells by 
augmenting the expression of MHC class II molecules and thereby facilitating the allergen-
presentation to Th2 cells. On the other hand, it induces isotype switching which leads to 
further IgE production by B cells 23. IL-13 stimulates in overlap with IL-4 multiple features of 
asthma such as IgE production, airway hyperreactivity, goblet cell hyperplasia, smooth 
muscle hyperplasia and subepithelial fibrosis. The most important Th2 associated cytokine 
associated with eosinophils is IL-5, which regulates eosinophilic growth, maturation, 
differentiation, survival, activation and recruitment to the airways 23-25. Several other, newly 
described cytokines are known to actively contribute to the development of allergic airway 
diseases, like IL-9 which exerts synergistic actions with IL-4 and 13, or IL-25 which 
stimulates release of IL-4 and 5, thereby, in turn, promotes IgE synthesis and eosinophilia 26. 
Depending on the intensity and duration of the stimuli, approximately 60% of asthmatic 
patients are dual responders, i.e.  the early asthmatic response is followed by a late asthmatic 
response (LAR). LAR starts between 3-4 hrs after the allergen provocation, peaks between 6 
and 12 hrs and resolves within 24 hrs. Via cytokine-induced endothelial expression of 
leukocyte adhesion molecules such as E-selectin or ICAM-1, the recruitment of leukocytes 
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into tissues can be easily promoted. Inflammatory cells such as eosinophils, neutrophils, T- 
cells, macrophages, dendritic cells, endothelial cells, airway smooth muscle cells and 
bronchial epithelial cells produce a variety of cytokines and chemokines which elicit airway 
wall thickening, subepithelial fibrosis, goblet cell hyperplasia, myofibroblast hyperplasia, 
airway smooth muscle cell hyperplasia and hypertrophy. 
Thus, the late phase of the asthmatic response is characterized by excessive inflammation of 
the airways resulting in structural changes. In chronic allergic asthma this re-structuring is 
referred to as airway remodeling 27; inflammation affects all layers of the airway walls and is 
associated with changes in the epithelium including an increased number of mucus producing 
goblet cells, increased secretion of chemokines and cytokines, substantial inflammation of the 
submucosa, enhanced development of myofibroblasts, augmented vascularity and increased 
thickness of the muscular layer of the airways with greater size, number and function of 
smooth muscle cells 28. 
3. Mouse models of allergic asthma  
Although insights from mouse asthma models can only approximate human clinical disease, 
they are widely used to investigate the immunological mechanisms and inflammatory 
responses in allergic asthma.  
The induction protocols for acute or chronic asthma in mice are principally all based on 
systemic intraperitoneal priming followed by respiratory boosts with the respective allergen. 
Airway provocation is usually performed via aerosolization, intranasal or intracheal 
administration and can take one to nine days in the acute and four to twelve weeks in chronic 
mouse models 29. Systemic sensitization is most often described to be achieved by 
administration of the allergen either dissolved in PBS or administered with alum as an 
adjuvant 30. Mice which are exposed to aerosolized antigen in the absence of systemic 
immunity do not develop lung disease 31, 32. However, primary systemic sensitization can also 
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trigger systemic immune and non-specific airway responses on consecutive airway challenges 
with an unrelated, not cross-reactive, secondary allergen 33. 
The most commonly used mouse strain for allergen challenges is BALB/c as it is known to 
develop a solid, Th2-biased immunological response 34. However, also other strains like 
C57BL/6 and A/J mice have been successfully used for allergen challenge studies 35. 
Ovalbumin (OVA) derived from chicken egg is frequently used as a model allergen because it 
induces a robust pulmonary allergic inflammation in mice and is, moreover, relatively 
inexpensive. OVA, however, is seldomly implicated in human asthma, therefore sensitization 
with alternative allergens with higher clinical relevance, such as house dust mite 36 or grass 
pollen 37, are envisaged.   
Upon sensitization and airway challenges with the respective allergen, eosinophilic 
infiltration of the lung, airway hyperresponsiveness (AHR), increased IgE, mucus 
hypersecretion and, eventually, airway remodeling in mice are observed 31.  
Due to the relative short-term nature of many acute models, the key feature of asthma, namely 
airway remodelling is minimal and other parameters like eosinophilic infiltration and AHR 
are transient. Airway inflammation and AHR have been shown to resolve within a few weeks 
after the final allergen challenge. However, acute models have provided important 
information about inflammatory processes like the role of Th2 cells in asthma and the 
implication of eosinophils in AHR. Furthermore, many cellular and molecular targets for the 
treatment of asthma could be evaluated in the acute models, e.g. IL-4 and IL-5 antagonists 38-
40
. 
Chronic allergen challenge models which more closely mimic the chronic aspects of human 
asthma with respect to epithelial hypertrophy, subepithelial fibrosis and limited smooth 
muscle hyperplasia have been established by several groups 41-43. The problem with chronic 
models is that long-term challenges of mice often induce tolerance and rather downregulate 
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inflammation and AHR 44. Thus, the strain of mice, the allergen concentration and the route of 
administration are critical factors that determine whether tolerance is induced or not. 
Major differences between mouse and human physiology have to be considered when 
working with mouse asthma models: whereas patients suffer from methacholine induced 
AHR even in symptom free periods, mice exhibit only transient methacholine-induced AHR 
after airway provocation. Furthermore, an apparent lack of eosinophil degranulation could be 
observed in the majority of mouse asthma models and there is no or little recruitment of mast 
cells into the airway wall or epithelium 45-47.   
Although mouse models of allergic asthma have limitations that need to be considered when 
extrapolating findings from mouse to the human disease, many questions on susceptibility, 
pathogenesis, airway remodeling, immunological memory, and treatment are currently and 
successfully answered in mouse models 31. 
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4. Treatment strategies for allergy and asthma 
As exposure with allergens is the prerequisite to develop any allergic disease, allergen 
avoidance of allergen exposure before or after sensitization should be beneficial as primary or 
secondary prophylaxis. This is difficult for ubiquitary allergens such as grass pollens. 
At present, the only curative treatment with long-term effects in patients is allergen-specific 
immunotherapy (SIT), which involves the administration of allergen extracts aiming to induce 
tolerance to those allergens which cause symptoms in the individual. The clinically most 
effective form of SIT is subcutaneous immunotherapy (SCIT), which comprises repeated 
subcutaneous injections of the sensitizing allergens. Typically, patients receive a course of 
injections, starting with a very low allergen dose being built up gradually until a plateau or 
maintainance dose is reached. The “build-up phase” consists of several weekly injections and 
is followed by a “maintainance phase”, in which the allergen is given in a 4 to 6-week interval 
over a period of 3-5 years 48. The beneficial effects of SIT comprise the induction of allergen-
specific T regulatory cells which produce anti-inflammatory cytokines IL-10 and TGF-β and 
thereby downregulate the activity of effector Th2 cells, suppress IgE production and induce 
isotype class switching to IgA and IgG4 49, 50. IgG4 antibodies, also known as allergen-
specific blocking IgG, compete with effector cell bound IgE for allergen binding and 
therefore may prevent the activation of mast cells and basophils. In the same way, IgE 
facilitated allergen presentation via binding to low affinity IgE receptor CD23 on antigen-
presenting B cells is impeded 51. When complexed with an allergen, blocking antibodies can 
moreover mediate inhibitory signals via co-aggregation of the IgG receptor FcγRIIb and IgE 
receptor FcεRI and, thus, again avoid activation/degranulation of effector cells and, more 
importantly, inhibit IgE synthesis from B cells 52-54. 
However, the benefit of SIT becomes less favorable when considering the increased risk of 
allergen-induced, IgE-mediated systemic side effects and de novo sensitization against other 
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components of the allergen extracts administered. To improve safety, sublingual 
immunotherapy (SLIT), i.e. application of allergens via the oral mucosa has only recently 
gain acceptance. Although higher doses of allergen are used, side effects are relatively mild 55. 
However, the treatment benefit was found to be approximately half of that achieved with SIT 
56
.  
In the past few years, intensive research has been done to improve efficacy and safety of 
immunotherapy in allergy. Among the current developments of SIT is the generation of 
recombinant allergens which allow consistency in quality and quantity of the active ingredient 
57
. However, as IgE reactivity is still preserved, modified versions like hypoallergenic 
recombinant molecules, deletion mutants, fragments or peptides have been developed 58-62. 
Many of these approaches include T cell epitopes aiming to stimulate peripheral T cell 
tolerance while lacking IgE antibody binding sites to exclude the risk of IgE mediated 
crosslinking. Nevertheless, several studies using T cell peptides for treatment of allergic 
airways disease have instead reported on the recruitment of inflammatory T cells and 
manifestation of chronic allergic inflammation 63, 64. 
Another possibility to bypass the activation of allergen-specific T cells in this aspect is the use 
of mimotopes, which exclusively mimic B cell epitopes of allergens. As B cell epitopes most 
often appear conformational and discontinuous in nature, phage display offers an elegant 
method for defining structures that mimic binding sites for antibodies 65. In a peptide phage 
library, random oligonucleotides are inserted into the genome of a filamentous bacteriophage 
for subsequent presentation in context with either minor phage coat protein pIII or major coat 
protein pVIII. In a process called “biopanning”, repetitive screening of phage libraries with 
allergen-specific antibodies of interest is performed.  
Besides peptide libraries, antibody-derived phage display systems are also suitable for 
selection of potential B-cell epitope-specific candidates in biopanning. For the construction of 
an e.g. combinatorial Fab antibody phage library, cDNAs of heavy and light chains from the 
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B cell repertoire of an allergic individual are combined and presented by phagemid systems 
66
. When screening with anti-allergen Ig, the selected Fab represents an anti-idiotypic 
specificity. It represents a complete antigen and is suitable for immunizations. In contrast, a 
mimotope peptide is a hapten, being much smaller in size and therefore requires T-cell help to 
gain sufficient immunogenicity. Bystander T cell help must be provided by e.g. immunogenic 
carriers or immunostimulatory agents, such as KLH or tetanus toxoid (TT) 67. Moreover, due 
to the monovalent nature of anti-idiotypic Fab fragments, the risk of IgE crosslinking on 
effectors cells is limited 68. In the past we and other groups could identify mimotopes and 
anti-idiotypic Fabs from a number of different allergens 68-72. It could be shown that the 
selected clones were able to interfere with the high affinity binding of IgE and to trigger 
allergen-specific immune responses without the activation of allergen-specific T cells 73, 74 .  
In previous studies, our group identified a peptide mimotope of grass pollen major allergen 
Phl p 5 which was later on applied for therapeutical treatment in a mouse model of acute 
allergic asthma. For the first time it was shown that a mimotope could successfully 
downregulate allergic airway inflammation and moreover protect from disease upon allergen 
re-challenge by airway provocation 37.  
Besides protein-based immunization strategies, application of allergen-encoding DNA in 
rodents has yielded promising results in the field of allergy. Side effects which are connected 
to protein immunization like IgE cross-linking or de novo induction of anaphylactic 
antibodies could be effectively avoided upon the administration of pure DNA.  DNA vaccines 
consist of the foreign gene, e.g. the allergen of interest, which is cloned into a bacterial 
plasmid engineered for optimal expression in eukaryotic cells 75.  
Experiments in animal models have demonstrated that injection of plasmid DNA induces a 
Th1 cytokine milieu being efficient either in a preventive or therapeutic approach 76-79. 
Plasmid DNA is taken up by either APCs or somatic cells like keratinocytes, which transcribe 
and translate the information into the respective allergen. As a result, peptides can be 
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presented via MHC I and thereby active Th1 cells which secrete IFNγ and drive B cells 
towards IgG production or via MHC II which leads in conjunction with Th1 cells to activation 
of cytotoxic T cells.  
Immunization of DNA vaccines can be performed via several administration routes including 
epidermal, mucosal, intramuscular, intravenous or biolistic gene transfer. Injection of plasmid 
DNA into skin or muscle requires high amounts of DNA whereas the biolistic device (gene 
gun) renders immune responses with at least 100-fold lower quantities of DNA. However, 
gene gun bombardment was in the past predominately reported to be associated with a Th2 
biased immune response 74, 80. 
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AIMS 
We previously generated peptide mimotopes and anti-idiotypic Fab fragments being B cell 
epitope mimics and completely devoid of allergen-specific T cell epitopes. As a model 
allergen, we chose grass pollen major allergen Phl p 5. The overall intention of this thesis 
work was to achieve for the first time the proof of concept for a therapeutic mimotope vaccine 
in a mouse model of allergic disease.  
Therefore, our first aim was to adapt a mouse model of acute allergic asthma to sensitization 
with grass pollen allergen Phl p 5 and to evaluate its pathophysiological significance. For this 
we used a novel, open-circuit indirect calorimetric system which enabled us to measure 
respiratory gas exchange and motor activity of mice within the acute asthma attack. To dissect 
allergen-specific asthma from non-specific airway provocation, we introduced an irrelevant 
antigen for airway challenge.  
The aim of the second study was to examine for the first time the therapeutic efficacy of a 
decameric peptide mimotope termed Phl mim 5 by use of the previously established memory 
mouse asthma model. We evaluated whether mimotope vaccination would a) downregulate 
airway inflammation and moreover b) protect from acute asthma upon re-exposure to the 
allergen. Re-challenge with the aerosolized allergen was performed after vaccination therapy. 
Effects on the humoral and cellular immune response were analyzed in sera, bronchial lavage 
fluid (BAL) and lungs.  
The third and last aim of the thesis was to investigate whether an immunization strategy with 
minigenes would be advantageous over peptide administration. As genetic vaccination has 
shown to efficiently downregulate ongoing Th2 immune responses in rodent models in the 
past few years, we decided to construct a DNA vaccine encoding the mimotope sequence and 
tested whether it would elicit allergen-specific immune responses in naive BALB/c mice.  
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As the allergen route might critically affect the outcome of the immune response, we intended 
to compare head to head two different routes of gene vaccine administration, i.e. intradermal 
injection and gene gun immunization.  
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Anti-Ids in Allergy: Timeliness of a Classic Concept
Julia Wallmann, MSc, Isabella Pali-Scho¨ll, PhD, and Erika Jensen-Jarolim, MD
Abstract: Anti-idiotypic antibodies (anti-ids) are part of natural
immune responses with regulatory capacity. Their effect on an
antigen-specific, so-called Ab1 antibody response, is dependent on
1) the original antigen, which they mirror, being Ab2 antibodies, and
2) their isotype. In the case of IgE-mediated allergy, natural anti-ids
against allergen-specific IgE represent internal images of allergen
molecules. A key biologic feature of allergens is that they can
crosslink IgE, expressed by B-lymphocytes or passively bound via
high affinity receptors to effector cells, which renders cellular
activation. Therefore, the IgE cross linking capability of anti-ids
determines whether they dampen or enhance immediate-type hyper-
sensitivity. Correspondingly to classic antiallergen blocking IgG anti-
bodies, anti-ids may also interact with inhibitory FcRIIb receptors and,
thereby, down-regulate TH2-type inflammation. Anti-ids and other
B-cell epitope mimetics, like mimotopes and DARPins, represent an-
tigen surrogates, which can be used for vaccination. Intriguingly, they
may induce antibody responses without activating potentially proin-
flammatory, antiallergen T-lymphocytes. Taken together, collective
evidence suggests that anti-ids, although representing immunologic
classics, are a timeless concept in allergology.
Key Words: anti-idiotypes, allergy, vaccination, FcRI, FcRIIb,
blocking
(WAO Journal 2010; 3:195–201)
INTRODUCTION
Besides a specific antigen binding site, antibody moleculespossess antigenic determinants themselves. When these
epitopes are located within the variable region of an antibody,
they are designated idiotopes. Hence, each Fab arm of an
antibody displays a set of idiotopes, representing epitopes for
complementary antibody molecules (Fig. 1), so called anti-
idiotypic antibodies (anti-ids). Anti-ids are part of regular im-
mune responses and are thought to result in a web of interacting
idiotypes. Classically, Jerne defined the order of an antibody
response as follows: Antibody Ab1 is produced in response to
an antigen and induces the production of anti-idiotypic Ab2,
which can in turn stimulate the synthesis of an anti-(anti-
idiotypic) antibody Ab3, and so forth (Fig. 1). Anti-idiotypic
antibodies (Ab2) can be classified into several categories
according to their fine specificity (Fig. 2): 1) conventional
Ab2 antibodies recognize idiotopes of Ab1 outside of its
antigen binding site, but still within the variable region; 2)
internal image Ab2 antibodies recognize idiotopes directly
within the antigen binding site of Ab1 and, therefore, mimic its
original antigen epitope like “internal images”; 3) in case the
idiotope recognized by Ab2 is not completely overlapping but
close to the antigen binding site of Ab1, it may still be able to
interfere with the antigen binding and is called Ab2. Conse-
quently, binding of antigen by Ab1 is not affected by Ab2, may
be blocked by Ab2 and is completely blocked by Ab2.
ANTI-IDS IN EXPERIMENTAL STUDIES:
THE BEGINNING
The first experiments regarding anti-ids were animal stud-
ies, which were performed to evaluate the effect of anti-ids either
on an upcoming or ongoing immune response.
For instance, Cosenza and coworkers designed a mouse
study where they used a monoclonal IgA antibody derived from
the myeloma cell line TEPC 15, specific for the hapten phos-
phorylcholine.1 To generate an anti-idiotypic immune response,
mice were immunized with the myeloma antibody Ab1 and sera
were harvested. Parallel, they immunized another group of
BALB/c mice with heat-killed pneumococci to induce a phos-
phorylcholine-specific Ab1 response. As a proof for the induc-
tion of specific antibodies, erythrocytes attached to either pneu-
mococcal C polysaccharide or phosphorylcholine were
incubated with the splenocytes from the latter group of mice,
resulting in hemolytic plaques because of immune complex-
mediated complement activation.2 Importantly, when spleen
cells were preincubated with the anti-idiotypic serum generated
upon immunization with myeloma IgA, plaque formation was
specifically inhibited because of blockage of Ab1. This principle
was later also shown for anti-ids directed against Ab1 specific
for group A streptococcal antigen.3
However, anti-ids could not only inhibit effector re-
sponses, but also prevent de novo induction of specific
immune responses in vivo. Naive BALB/c mice were admin-
istered the anti-idiotypic serum derived from immunization
with TEPC myeloma IgA and subsequently intravenously
immunized pneumococci. Antibody responses to phosphoryl-
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choline but not to an irrelevant control allergen were com-
pletely blocked. Thus, anti-ids were discussed to be directed
also against membrane immunoglobulins of naive antigen-
specific B cells. Accordingly, it was hypothesized that mem-
brane and secreted immunoglobulins share similar variable
domains even when belonging to different isotypes.1,4 The
key result of these studies was, however, that anti-ids act at
the cellular level to specifically suppress antibody formation.
Hart and his group generated anti-ids by immunization of
rabbits with p-azophenylarsonate-specific mouse antibodies.
When naive mice were then injected with the anti-idiotypic
rabbit serum and afterward challenged with KLH (keyhole
limpet hemocyanin)-linked azophenylarsonate, de novo anti-
body formation was suppressed up to 97%.5 However, the
suppression was not complete. This might have been because of
the appearance of antibody responses directed against either the
carrier protein KLH or the hapten (p-azophenylarsonate) as
such. It seemed probable that the induced antiphenylarsonate
antibodies (and their anti-ids), induced by carrier-hapten immu-
nization, possessed idiotypes other than those elicited by either
KLH or the hapten. Again, the conclusion of this study was that
anti-ids acted suppressive at the cellular level via binding to
immunoglobulins expressed by B-lymphocytes.
Furthermore, it became apparent that T cell receptors
carry idiotypes similar to those of immunoglobulins, meaning
that anti-ids could potentially regulate both, B-lymphocyte
and T-lymphocyte function.6 The idiotypic relationship be-
tween hypervariable domains of T and B lymphocyte recep-
tors has indeed been repeatedly documented.7–10 Further-
more, it has been shown that anti-ids can mediate cooperation
between T and B lymphocytes (Fig. 3C). Furthermore, when
B-lymphocytes expressing membrane Ab1 (mAb1) are tar-
geted by Ab2, they internalize and process the anti-id (Fig.
3B) like the original antigen (Fig. 3A). Consequently, an
anti-idiotypic peptide of Ab2 is presented in an MHC II
context to T cells, again resulting in T cell-help. This would
be an additional explanation for how B-lymphocytes recruit T
cell help. In the early 1980s, also Blaser et al identified
idiotypes on specific T-helper cells similar to the antigen-
specific IgG. However, they dissected an antihapten from an
anticarrier response and proposed that, in contrast to the
above, especially an anticarrier anti-id might block T-helper
cell function, rendering reduced antibody production.11
Taken together, already at that timepoint, functional
similarity between antigen and anti-id could be shown. There
was mostly evidence that administration of anti-ids sup-
pressed specific idiotype production.4,12 However, other
studies13 suggested that under certain conditions anti-ids
could enhance immune responses. For instance, adminis-
tration of anti-ids of the IgG1 isotype raised in A/J mice
against an antistreptococcal antigen A antibody (Ab1)
could prime animals for a secondary boost to the antigen.
Interestingly, anti-ids of the IgG2 isotype were rather
FIGURE 1. The anti-idiotypic network amplifies antigenic
signals. (A) An antibody Ab1 is produced in response to a
specific antigen. (B) With a defined idiotype, Ab1 induces
the production of an anti-idiotypic antibody Ab2. This Ab2
may resemble the original antigen as an internal image. (C)
Ab2 can stimulate the synthesis of an anti(anti-idiotypic) anti-
body Ab3 which principally is of the same specificity as Ab1.
FIGURE 2. Categories of anti-idiotypic antibodies. Ab2
antibodies recognize idiotopes outside the antigen binding
site, but still within the variable region of Ab1. Ab2 recog-
nizes idiotopes close to the antigen binding site of Ab1 and
thus may interfere with the antigen binding. Internal image
Ab2 binds directly within the antigen binding site.
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associated with suppressive effects on naive, antigen-
sensitive B cells.12 Therefore, besides antigen-specificity
of the anti-idiotypic system, also the induced isotype
seemed to contribute to the regulatory capacity of anti-ids.
NATURAL ANTI-IDs TO ALLERGEN-SPECIFIC IGE:
QUALITATIVE AND QUANTITATIVE STUDIES
In allergy research, Malley et al reported the influence of
anti-ids on primary and secondary IgE antibody responses to
timothy grass (Phleum pratense) pollen extract.14 An anti-idio-
typic antibody was produced to the grass pollen-specific IgE and
was administered intraperitoneally followed by immunization of
mice with timothy grass pollen extract. This anti-id profoundly
prevented IgE production toward the allergen extract, and sup-
pressed even up to 75% of the IgE response to a secondary
boost. This suppression persisted for at least 35 days.14
Despite optimistic results such as these, the role of anti-
idiotypic immune responses in humans induced during long-
time immunotherapy could at that time only be postulated.
Bose and colleagues did the first quantifications of
anti-ids in rye grass-allergic patients’ sera.15 Rye I-specific
IgG anti-ids were purified from a ryegrass allergic patient
who had been previously hyposensitized. In vitro, these IgG
specifically blocked the binding of IgE and IgG to group I
allergens of rye grass in sera of 20 individual allergics. This
result pointed toward the recurrence of idiotypes and a
constricted repertoire of human antibodies specific for an
allergen. The authors discussed similar idiotopes of IgG and
IgE within their antigen binding site. However, in this study
it remained unclear whether the same anti-ids were able to
inhibit antigen binding to both, IgE and IgG.
A functional distinction between paratope-associated
idiotopes versus bystander idiotopes (ie, idiotopes located out-
side the antigen-binding site) of IgE and IgG was made by the
group of Saint-Remy.16 They observed cross-reactivity of house
dust mite-specific IgE and IgG, but only with respect to by-
stander idiotopes.17 They inhibited Ab1-Ab2 interactions with
house dust mite allergens and thereby found that the majority of
natural anti-ids in mite-allergic patients was of the Ab2 type,
thus resembling internal images of the allergen. Still, the authors
suggested the epitope-specificity of IgE and IgG to be different.
Interestingly, anti-ids specific for ragweed were also
found in nonatopic individuals although to a much lesser
extent than in allergic and immunotherapy-treated pa-
tients.18–20 The authors proposed that anti-ids detected in
nonatopics probably represent a basal level of Ab1/Ab2
responsiveness because of the presence of allergen-specific
IgG, but not IgE antibodies, in health.
Anti-id levels in untreated patients sensitive to grass
pollen allergen Lol p I and in hyposensitized patients were
compared with levels in allergic donors not sensitive to Lol p
I, and nonallergic donors by Bose et al using sepharose
purification. Via binding to radiolabeled, affinity-purified
F(ab)2 fragments of Lol p I monoclonal antibodies, the
amounts of anti-ids and the ratio to allergen-specific antibod-
ies were calculated.21 Again, anti-ids were observed to be
present not only in allergic individuals but also in nonaller-
gics, although the latter did not show any detectable IgG or
IgE (Ab1) anti-Lol p I. Anti-id levels in allergics were shown
to directly correlate with the level of pollen exposure or the
hyposensitization status. In the majority of patients treated by
immunotherapy an inverse relationship between serum levels
of anti-Lol p I IgE and IgG antibodies (Ab1) and of anti-ids
(Ab2) could be observed. An initial increase of specific
idiotype (Ab1) levels was associated with a drop of the anti-id
(Ab2) level. However, like during hyposensitization, the
anti-id level later on increased toward a plateau. An increase
of Ab2 was also reported by Castracane et al in a ragweed
allergic human patient undergoing immunotherapy. They
used an antiragweed specific F(ab)2 fragment for coating in
a solid phase assay.19,20 In line with earlier observations by
Oudin and Cazenave, it had to be considered that a proportion
of the raised anti-ids was most probably not specific to Lol p
I, but could have also encountered similar idiotypes derived
from different allergens.21,22 Hebert and colleagues measured
elevated anti-id levels in sera of hyposensitized patients by
the use of 3 different murine monoclonal anti-Lol p I anti-
bodies.23 These murine antibodies were shown to share cross-
reactive idiotypes with human anti-Lol p I IgE and IgG
antibodies and therefore suitable in this study.24
FIGURE 3. Mechanisms of anti-idiotypic antibodies on B
(B) and T cell (T) interaction. (A): B cells recognize antigen
by membrane-expressed immunoglobulins (mIg) and receive
bystander help from T-helper cells. (B) Alternatively, an an-
ti-id may bind to mIg of a B-cell. This leads to processing
and MHCII display of an anti-idiotypic peptide rendering T
cell activation and help. (C) Because of idiotypic similarities
between B and T cell receptors, an anti-idiotypic antibody
may also force cooperation between B and T cells by bind-
ing to both. (D) Inhibition of B cell proliferation is achieved
by simultaneous binding of the anti-id to its corresponding
idiotype on mIg and via its Fc domain to FcRIIb on the
B-cell.
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THE FUNCTIONAL ROLE OF ANTI-IDS
IN ALLERGY
Levels of anti-ids were generally found to be higher in
healthy individuals than in untreated atopic patients. In the
latter, levels can be elevated by immunotherapeutical treat-
ment to the levels found in healthy volunteers.20,24
Valacer and colleagues inhibited IgE binding from
allergic patients to ragweed antigen by administration of
anti-ids purified from sera of nonallergic individuals. Strik-
ingly, this effect could be achieved although no allergen-
specific IgG or IgE could be detected in the sera of the
healthy donors. The authors discussed that anti-ids in healthy
persons could regulate the IgE response by suppressor mech-
anisms.25 Indeed, a dramatic suppressive effect of anti-ids on
the IgE response was observed in experimental studies. A
single anti-id directed against an idiotope of a murine anti-
body specific for a major epitope of grass pollen allergen Lol
p IV down regulated the allergen-specific IgE response pro-
foundly, whereas levels of other isotypes, for example, IgG1
and IgG2 were less affected.26
The enthusiasm about potential beneficial effects of anti-
ids in the course of immunotherapy was dampened by the
sudden awareness that anti-ids against allergen-specific IgE
antibodies potentially could also target IgE bound to effector
cells. This could lead to either mediator release by IgE-cross-
linking (Fig. 4B) like it is the case with the original antigen (Fig.
4A), or to the inhibition of allergen-induced release (Fig. 4D). In
fact, Geha et al demonstrated that passive cutaneous adminis-
tration of an antitetanus toxin anti-id in a human patient elicited
positive immediate-type skin reactions.27 In another study, pas-
sive cutaneous anaphylaxis experiments in rats were chosen to
analyze the in vivo effects of anti-ids on mast cell bound IgE.
Anti-ids were raised in syngeneic mice by immunization with
dinitrophenol (DNP)-specific mouse monoclonal IgE. The anti-
idiotypic serum induced a passive cutaneous anaphylactic reac-
tion in skins of rats sensitized with the DNP-specific mouse IgE.
In contrast, the same anti-id did not elicit a reaction in DNP-IgE
sensitized rats when they simultaneously were passively admin-
istered grass pollen-specific IgE. Thus, a specific anti-id seemed
to be more effective in histamine release when less IgE speci-
ficities were present in the sensitized individual. From this it was
concluded that anti-idiotypic stimulation within a polyclonal
response, like in human atopy, would rather inhibit mediator
release (Fig. 4C). Furthermore, successful immunotherapy was
considered to rely on continuous anti-id targeting of the mast
cells rendering internalization and, therefore, depletion of cell
bound specific IgE.28
The capability of human anti-idiotypic IgG purified
from mite allergic patients to recognize cell bound IgE
idiotypes of other donors, and to induce mediator release of
basophils in the absence of allergen was demonstrated.29
Consequently, the possibility that degranulation in response
to anti-ids could be a general event in allergy was proposed.
However, the degranulating activity of anti-id preparations
varied from one patient to the other. Several mechanisms
were discussed: First, the precise specificity of anti-ids could
play a role, because framework idiotopes could be private
and, in contrast, paratope-associated idiotopes of antibodies
were found to be more common among different individuals.
Hence, the relative proportion of these 2 types of anti-ids
could explain the varying degranulating activity of single anti-id
preparations on basophils of different donors. Secondly, the
authors discussed the repertoire of anti-ids to be dependent on
the individually varying antiallergen IgE response, limiting their
degranulation capacity when testing basophils of other donors.
Taken together, the impact of anti-ids in the regulation of
IgE antibody responses to allergens has at that time not been
revealed to the same extent as for infectious diseases or in
malignancies.30–32 However, genetic engineering of antibodies
opened novel methodological possibilities for precise investiga-
tion of the effects of anti-ids in the effector phase of type I
allergy. As many studies previously were based on mouse
monoclonal anti-ids, it was difficult to extrapolate the findings to
the human setting. Therefore, the group around Shakib intended
to engineer murine/human chimeric anti-ids and the correspond-
ing antiallergen IgE,33 taking Der p 1 as a model allergen.
Testing these chimerized IgE-anti-idiotypic antibodies on
FcRIIb transfected cells and purified basophils, they found an
inhibition of the degranulation through the anti-ids. Interestingly,
a novel mechanism of action was proposed, involving FcRIIb-
binding by the Fc domain of the anti-idiotypic IgG, and,
FIGURE 4. Mechanisms of anti-idiotypic antibodies on ef-
fector cells. Mediator release of effector cells (E) is triggered
by cross-linkage of 2 receptor-bound IgE either via (A) rec-
ognition of the antigen or (B) the anti-id. (C) Effector cell
inhibition is achieved by binding of the anti-id to its specific
idiotype within a polyclonal response. (D) Cross-linkage of
FcRI and the inhibitory FcRIIb receptor via an anti-idiotypic
IgG antibody also inhibits degranulation.
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consequently, cellular inhibition through the associated ITIM-
motif of this receptor (Fig. 4D).34 In this context it is of interest
that also allergen-specific IgG may recognize allergen already
complexed with mIgE on B-lymphocytes or with IgE bound to
the high affinity receptor. Upon simultaneous binding to
FcRIIb, allergen-specific IgG has been shown to down regulate
not only effector cells, but also B-lymphocytes.35,36 Therefore,
we postulate here that similarly anti-ids may exploit this mech-
anism and act on the B cell level, too (Fig. 3D).
Interestingly, anti-ids may not only dampen the allergic
response after allergen immunotherapy, but may also have a
protective function in offsprings of allergic mothers. In a
mouse model, the maternally derived anti-id against allergen-
specific IgE was shown to induce IgE suppression in the
offspring which was long-lasting and dose-dependent.37 As
molecular modeling ruled out an internal image function of
the anti-ids, possibly also here the binding to FcRIIb could
contribute to the protective function.
ANTI-IDS PRIME AND ENHANCE
ALLERGEN-SPECIFIC IMMUNITY
It had been suggested that anti-ids function differently
in healthy, allergics, or hyposensitized patients. Bose pro-
posed 1986 that anti-ids in allergics might function as “net-
work antigens”, mimicking the allergen and therefore being
able to accelerate an immune response.21 In accordance, an
anti-idiotypic Ab2 antibody raised by a monoclonal anti-
Lol p 1 antibody was able to successfully prime an aller-
gen-specific antibody response, as a subsequent boost
injection with the antigen Lol p I resulted in a further
increase of specific IgE and IgG antibody levels.38 The admin-
istration of anti-ids augmented both, idiotype specific and total
antibody responses against the allergen,38 a result that had been
predicted before by studies outside the field of allergy.39–41
However, the exact mechanism for the enhancing effect of an
anti-id resembling only a single epitope, remained unclear.
One may speculate that upon the administration of Ab2 the
induced Ab3 facilitates subsequent antigen presentation,
leading to epitope spreading. Especially the IgM isotype was
considered to potentiate the immune response against low
doses of antigen via the idiotypic network. A further expla-
nation could be that immune complexes formed after antigen
immunization directly stimulate antigen-specific B cells.42
VACCINATION WITH ANTI-IDS TO CONTROL
TOTAL IGE LEVELS
The immunotherapeutical potency of anti-ids for allergic
patients was not only investigated with respect to the allergen-
specific IgE response, but also regarding total IgE levels in
allergics. It had been shown previously that natural anti-IgE
isotype antibodies exist, which, depending on the epitope spec-
ificity of the Fc domain, may down-regulate or enhance the
effector function of IgE.43 Stadler et al aimed to generate
nonanaphylactogenic IgG antibodies through active immuniza-
tion with an anti-idiotypic antibody as an antigen surrogate.
When they used a beneficial, nonanaphylactogenic anti-IgE
antibody (termed BSW17) as a template, anti-ids could be
generated from a combinatorial phage library displaying the Fab
repertoire of a grass pollen allergic patient.44 According to the
principle of molecular mimicry, these anti-ids resembled an
epitope of the constant domain of IgE and actively induced
BSW17-like anti-IgE specificities in mice.45 Therefore, as an
alternative to passive anti-IgE therapy with, for example, oma-
lizumab, vaccination with anti-idiotypic molecules for active
induction of a protective anti-IgE response was envisaged by the
authors.
VACCINATION WITH ANTI-IDS TO CONTROL
ALLERGEN-SPECIFIC IGE LEVELS
In our own study, we generated anti-idiotypic Fab anti-
body fragments for IgE, which was specifically directed against
timothy grass pollen allergen Phl p 5.46 The phage library
containing the repertoire of a grass pollen sensitized individual,
which is described above,47 was this time used for screening
with allergen-specific IgE. Several high-binding Fab clones with
mimicry potential to the allergen’s IgE epitope could be isolated.
Upon immunization with clones in mice, antiallergen IgG could
be induced via molecular mimicry. Furthermore, these anti-
idiotypic Fabs resembled naturally occurring IgE epitopes of the
allergen as observed by sequence analysis and molecular mod-
eling.46 More recently, we applied one of the selected anti-
idiotypic clones in a memory mouse model of acute allergic
asthma to test whether it would be suitable for immunotherapy.
According to a protocol by Mojtabavi et al48 acute allergic
asthma was induced by injecting recombinant Phl p 5 intraperi-
toneally, followed by aerosol challenges with this allergen.
Subsequently, groups of mice with acute asthma were vacci-
nated with 1) the anti-idiotypic Fab fragment, or 2) control
antigen KLH before reinduction of acute asthma by an
additional allergen aerosol challenge.
Whereas the IgE and IgG1 antibody levels of all groups
remained unchanged during treatments, the extent of acute
eosinophilic inflammation upon rechallenge with aerosolized
allergen was much lower in the Fab-treated group compared
with the untreated asthmatic and the nonasthmatic groups (data
not shown). As the specific IgE levels were not affected, it is
tempting to speculate that the reason for this profound anti-
inflammatory property might be (similarly as with peptide mi-
motopes; see below) the absence of allergen-specific T cell
epitopes in the anti-ids.49 Surface plasmon resonance studies
indicated that high affinity polyclonal IgE may exhibit a binding
behavior similar to monoclonal antibodies, indicating that each
Phl p 5 allergen might only harbor a low number of IgE
epitopes.50 Consequently, the anti-idiotypic strategy is expected
to down-regulate IgE specificities being relevant and occurring
frequently in the grass pollen allergic population.
DISTINCT TYPES OF ANTI-ID LIKE MOLECULES
Although antibodies are widely used for therapeutic ap-
plications, they have some potential drawbacks in large scale
production including low expression yields and aggregation
tendency. In this context, phage display technology does not
only enable the selection of anti-ids, but also of peptide mole-
cules, which structurally mimic B cell epitopes and therefore are
called mimotopes.51 Several allergen mimotopes were already
defined by other working groups and ourselves, like for the
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panallergen profilin,52 the major fish allergen parvalbumin,53
birch pollen allergens,54 grass pollen allergens,46,55 or house dust
mite allergens.56 Mimotopes lack allergen-specific T-cell
epitopes and have been demonstrated to induce blocking IgG
antibodies without stimulation of allergen-specific T-helper
cells.49,54 Furthermore, when therapeutically applied in a murine
model of allergic asthma, they could, like reported here for an
anti-idiotypic Fab fragment, prevent acute lung hypersensitivity
and inflammation upon allergen rechallenge.57
Still, to achieve good quality of the immune response
towards the relatively short peptide mimotopes, bystander
T-cell help was needed. The immunogenic carrier for the
mimotopes was in that case KLH providing bystander T-
helper cell epitopes. Alternatively, tetanus toxoid (TT) could
also be chosen as an immunostimulatory agent because of its
promiscuous T-cell epitopes.58
Another possibility to enhance antigenic density is the
attachment of linear peptides to tyrosine backbones. The so
called multiple antigenic peptides (MAPs) can be synthesized in
a straightforward manner and allow a dense display, most often
as tetra- or octameric constructs.59 Taken up by antigen present-
ing cells (APC), they are processed to T-cell epitopes and can
activate T-cells too. However, controversial studies have raised
the question whether or not the addition of a promiscuous
T-helper epitope to a MAP is needed for achieving a sufficient
immune response upon MAP-vaccination.60
Another option to overcome the limitations of antibody
libraries are designed ankyrin repeat proteins (DARPins).
These DARPin libraries are a source of -hairpin structures,
which mimic naturally occurring repeat proteins, and play an
important role in innate immunity61; reviewed in.62 In a study
by Vogel et al, DARPin libraries were used to isolate ligands
against the variable region of the nonanaphylactogenic anti-
IgE antibody BSW17. Confirming the high specificity of the
identified anti-idiotypic DARPins, they successfully pre-
vented binding of BSW17 to IgE-sensitized rat basophils
expressing human FcRI.63 Recent molecular studies indi-
cated that hairpin scaffold libraries render mimetics, which
closely mimic the crystal structure of a native protein.64 We
are convinced that these novel developments will open up
new avenues for anti-idiotypic strategies in allergy research.
SYNOPSIS
From several studies in the past it has emerged that natural
anti-ids take part in the regulation of the immune response
including immediate-type hypersensitivity. Obviously, each an-
tibody response to an allergen is accompanied by the production
of anti-idiotypic antibodies and anti-antibodies, together com-
posing an idiotypic regulatory network. As predicted by Jerne,
several studies could indeed show on the molecular level that
anti-ids function as internal images of allergens. Thus, it may be
hypothesized that anti-ids for allergen-specific IgE potentially
nourish IgE memory in periods of allergen absence, like for
instance outside the pollen season. In experimental studies,
anti-ids have been able to specifically down-regulate, or vice
versa, boost allergen-specific immune responses. This can on the
one hand be because of the fact that they act on B- and
T-lymphocyte antigen receptors in either a nonproductive
(monovalent) manner or in a productive way by cross linking B
cell receptors, or crosslinking B with T-lymphocytes, thereby
forcing cellular crosstalk. Furthermore, anti-ids have been found
in nonallergic individuals, pointing toward a protective regula-
tory mechanism.
Despite controversial in vitro results of the influence
of anti-ids on the allergic response, levels of anti-ids
usually get elevated during the course of specific immu-
notherapy (SIT). Therefore, anti-ids that mimic the rele-
vant structural epitopes of an allergen are possibly attractive
candidates for immunotherapy. For vaccination, mimotopes or
DARPins represent novel anti-idiotypic alternatives. We pro-
pose that with anti-idiotypic tools, being synthetic or generated
from the patient’s antibody repertoire, immunologic disorders
like allergies could be manipulated.
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ABSTRACT 
Besides immunologically mediated specific hyperresponsiveness towards the allergen, 
hyperreactivity against nonspecific triggers is a problem of great clinical relevance in patients 
with allergic asthma. We applied indirect calorimetry combined with blood cell and gas 
analysis for studying physiological and immunological differences between specific and 
nonspecific events in a mouse asthma model of grass pollen allergy. 
Acute asthma towards allergen Phl p 5 was induced in BALB/c mice using an intraperitoneal 
prime and aerosol boost regimen. Allergen Phl p 5 or irrelevant antigen ovalbumin were used 
fro nebulization. Respiratory gas exchange and physical activity were measured before and 
after aerosol challenge by indirect calorimetry. Mice nebulized with Phl p 5 showed 
significant consumption of O2 and significant production of CO2, whereas physical activity 
was significantly reduced in both groups. Blood pH was also significantly decreased in both 
groups, accompanied by reduced bicarbonate levels in Phl p 5 challenged mice only. Phl p 5 
rather than OVA challenge resulted in substantially decreased white blood cell counts 
associated with lymphoid infiltration into lungs. In both challenge groups, however, red blood 
cell counts decreased. The results illustrate that indirect calorimetry in combination with 
blood cell and blood gas analysis explains the difference of pathophysiological changes in 
acute allergic asthma versus nonspecific airway irritation. We suggest that this mouse model 
renders novel insights contributing to the understanding and diagnosis of human disease. 
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INTRODUCTION 
Allergic asthma in humans is defined as a chronic inflammatory disorder of the airways and is 
characterized by airway inflammation, persistent airway hyperresponsiveness (AHR) and 
intermittent acute, reversible airways obstruction (Bousquet et al., 2000). Typically, the IgE-
mediated, immediate obstruction is followed by a late phase reaction triggered by the release 
of inflammatory mediators like leukotrienes from cells recruited to the lungs. This results in 
respiratory and, consequently, physical deficits of patients for a considerable time after an 
asthma attack. Additionally, in the absence of allergen, even exposure to unrelated antigens 
may trigger short-breathlessness and wheezing, again limiting lung function and thus, 
seriously affecting the patients’ quality of life.  
Although mouse models of allergic asthma exhibit some limitations compared to the human 
disease, they have provided important information about the conditions necessary for allergen 
sensitization. The common basis for the induction of allergic asthma in mice is systemic 
sensitization followed by pulmonary challenges with the allergen. The asthma phenotype in 
mice mirrors the setting in human patients and is characterized by eosinophilic lung 
inflammation, increased Th2-type antibody isotype levels, mucus hypersecretion and airway 
hyperresponsiveness. However, the expression of each of these parameters can vary within 
the disease, dependent on the sensitization protocol used (Epstein, 2006).  
We have previously adapted an acute asthma model in BALB/c mice for proof of concept 
studies of the therapeutic efficacy of Phl p 5 mimotope vaccines. Although the established 
airway inflammation was profoundly counterbalanced and protection from an allergen 
rechallenge could be achieved (Wallmann et al., 2010), the question remained how significant 
this asthma model would mimic the clinical setting. Therefore, in this study we evaluated this 
mouse model for significant effects on respiratory gas exchange. 
Allergen-specific experimental asthma was induced in BALB/c mice, which included aerosol 
challenges with the specific allergen in one group, and added ovalbumin (OVA) from chicken 
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egg white as an irrelevant control antigen to compare and distinguish between specific 
allergen-induced asthma and nonspecifically triggered hyperreactivity in the hypersensitive 
animals. We used for the first time an open-circuit indirect calorimetry system (Pospisilik et 
al., 2010), which enabled us to analyze respiratory gas exchange of allergic mice before, 
immediately after and 48 hrs after aerosol challenges. By the use of an integrated infrared 
beam, we recorded the number of movements of mice simultaneously. Additionally we 
measured arterial blood parameters and evaluated blood cell counts in all naive and test 
groups of mice. To morphologically and immunologically describe differences in airway 
inflammation as a consequence of aerosol provocations with either specific or unspecific 
allergen/antigen, histochemistry and cytokine profiling were performed.  
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MATERIALS AND METHODS  
Immunization of mice 
Female BALB/c mice (n=20) were immunized intraperitoneally (i.p.) with rPhl p 5a (10 
µg/100 µl PBS) on days 0 and 21. Ten days later, mice (n=10) were aerosol challenged with 
nebulized rPhl p 5a (protein and plasmid kindly provided by Arnd Petersen, Research Institute 
Borstel, Germany) (0.25 mg rPhl p 5a/100 ml PBS/challenge or Ovalbumin from chicken egg 
white 1%/100 mL PBS/challenge) with an ultrasonic nebulizer (Kendall, Aerodyne X, MTE 
Medizintechnik, Oldendorf, Germany) for 60 min twice daily with a four hours interval, on 
two consecutive days (day 31 and 32). Control groups were sensitized either with rPhl p 5a 
(n=5) or PBS (n=5) on days 0 and 21 and aerosol challenged 10 days later with PBS. One 
mouse group (n=5) remained naive. Measurements were performed on day 31 before, 
immediately after (day 32) and 48 hrs after aerosol challenges (day 34). 
 
Respiratory gas exchange measurements  
Mice (n=10) were put individually into Oxylet system chambers (Bioseb, France) separately) 
connected to an LE400 airflow unit (Bioseb, France) providing constant airflow. In brief, 
room air was pumped into the chamber housing a single, unrestrained mouse. The rate of the 
air supply (l/min) was adjusted for each individual chamber according to the animal’s weight 
multiplied by 10 (i.e. 10ml air/g body weight /min). Oxygen (O2) and carbon dioxide (CO2) 
concentrations of automatically and continuously sampled air were measured using a highly 
sensitive and very fast response O2/CO2 sensor unit (LE 405 O2/CO2 gas analyzer, Bioseb, 
France). Data were recorded and analyzed using the Metabolism 2.1. software package 
(Panlab, Spain).
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Assessment of activity  
Activity was evaluated using InfraRed Actimeter frames equipped with infrared beam and 
detector units (Bioseb, France). Activity measurements were performed in parallel with 
respiratory gas analysis; on day 31 before aerosol challenges, on day 32 and on day 34. 
 
Arterial blood gas analysis and differential blood cell counts  
Arterial blood samples from the tails of mice were taken and measured by a radiometer 
ABL800 FLEX (Wiener Neudorf, Austria). Differential blood cell counts were performed 
simultaneously with an Abbott Cell Dyn CD 3500 CS Analyzer, Vienna, Austria. 
Measurements were performed with naive mice on day 0 and immediately after sensitized 
mice were aerosol challenged with either Phl p 5 or OVA on day 31. In addition to blood pH, 
carbon dioxide partial pressure (pCO2) and bicarbonate levels (CHCO3-), concentration of 
hemoglobin (HGB) and hematocrit (HCT) were determined.  
Beside red blood cells (RBC) and white blood cells (WBC), HGB and HCT were confirmed 
by differential blood cell counts. 
 
Histopathology  
On day 35, mice were anesthetized (200 µl 2% Rompun (Bayer, Leverkusen, Germany) and 5 
ml Ketanest S (5mg/ml); 600 µl per mouse)) before fixation procedures were initiated. Lungs 
were fixed by intratracheal instillation which was performed with 4% paraformaldehyde in 
0.1 M Sörensen's phosphate buffer (12.0 mM NaH2PO4, 69.0 mM Na2HPO4) (pH 7.4), as 
described (Forkert, 1995). Lungs were embedded into paraffin as described earlier (Wegmann 
et al., 2005). Systematic uniform random samples (SURS) of lung tissue were analyzed 
according to standard methods. Paraffin sections of 2 µm in thickness were stained with 
periodic-acid-Schiff (PAS) for airway epithelial mucus. The surface area of mucus-secreting 
goblet cells (Sgc) per total surface area of airway epithelial basal membrane (Sep) and the 
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volume of PAS-stained epithelial mucus (Vmuc) per Sep were determined using a computer-
assisted Olympus BX61 microscope equipped with the newCAST stereology tool box 
(Visiopharm, Hoersholm, Denmark) according to following formulas: 
Sgc/Sep=∑Igc / ∑Iep 
Vmuc/Sep=LP x ∑Pmuc / 2 x ∑Iep 
∑Igc = sum of intersections of test-lines with goblet cells 
∑Iep = sum of all intersections of test-lines with epithelial basal membrane 
∑Pmuc = sum of all test-points hitting stored mucus 
LP = test-line length per test-point at final magnification (490x) 
The volume of lymphoid follicles (Vfol) per total surface area of airway epithelial basal 
membrane (Sep) was determined according to the formula: 
Vfol /Sep = LP x ∑Pfol / 2 x ∑Iep 
∑Iep = sum of all intersections of test-lines with epithelial basal membrane 
∑Pfol = sum of all test-points hitting mucus 
LP= test-line length per test-point at final magnification (490x) 
 
Eosinophilic infiltration 
Paraffin sections of 2 µm in thickness were stained with Congo Red, according to (Pali-Scholl 
et al., 2008), for the assessment of airway wall infiltration with eosinophilic granulocytes. The 
degree of infiltration within each field of view collected according to SURS, was ascribed to 
one of the three scores; (A) no (B) one or (C) two ore more eosinophils in the airway wall. 
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RNA isolation and quantitative reverse transcriptase polymerase chain reaction (qRT-
PCR) 
Total RNA was extracted using the Trizol Reagent from Invitrogen (Invitrogen, Lofer, 
Austria) according to the manufacturer’s instructions. RNA was quantified by measuring the 
absorption at 260/280 nm using a NanoDrop spectrophotometer (Nanodrop Technologies 
Montchanin, DE, USA). 3 µg of total RNA from each sample were reverse transcribed in a 
total volume of 20 µl using the high capacity cDNA reverse transcription kit (Applied 
Biosystems, Vienna, Austria), according to the manufacturer’s instructions. 2 µl of cDNA 
were used for amplification by qRT-PCR which was performed with POWER SYBR®Green 
PCR Master Mix on an ABI StepOnePlus Realtime PCR System (Applied Biosystems, 
Vienna, Austria). IL-4, IL-5 and IL-13 mRNA levels were quantified by the comparative 
∆∆CT method using the SDS software (Applied Biosystems, Foster City, CA, USA).  
For each of the samples, relative expression was normalized to the housekeeping gene 
Hypoxanthine-phophoribosyl-transferase (HPRT). Pooled cDNA of naive tissue was used as a 
calibrator and set the value 1; the relative expression levels of the other samples were 
compared hereto. Each sample was applied in duplicates. Following qRT-PCR program was 
used : 50°C for 2 min, 94°C for 2 min, followed by 40 cycles of 94°C for 15 s and 60°C for 
30 s. Primers were designed using Primer Express (Applied Biosystems) and were located on 
different exons to prevent amplification of potentially contaminating genomic DNA.  
Following primer sequences were used:  
IL-4:  fwd primer: ccatgcttgaagaagaactctagtgt 
  rev primer: attcatggtgcagcttatcgatg  
IL-5:  fwd primer: gaggcttcctgtccctatcataa 
rev primer: tacccccacggacagtttga  
IL-13: fwd primer: ccatctacaggacccagaggat 
rev primer: gggaggctggagaccgtagt 
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Statistical analysis 
Statistical comparison between groups was performed by the Mann Whitney-U test, using the 
software SPSS (version 17.0 for Windows). Differences were considered statistically 
significant at P < 0.05. 
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RESULTS 
Challenging asthma with the specific allergen but not with an unspecific control antigen 
alters CO2/O2 exchange levels  
To determine differences between allergic mice after allergen-specific and nonspecific 
pulmonary challenges, we evaluated respiratory gas measurements using indirect calorimetry. 
This system allows the determination of the respiratory gas exchange, i.e. CO2 production and 
O2 consumption of single mice. 
Mice were primed i.p. with Phl p 5 followed by Phl p 5 aerosol challenges 10 days later to 
induce allergic asthma. Another group of mice was primed with Phl p 5 but aerosol 
challenged with irrelevant control antigen chicken egg white ovalbumin (OVA) from chicken 
egg white. Respiratory gas analysis in metabolic cages was performed before, immediately 
after and 48 hrs after aerosol challenges (Fig.1; sensitization and challenge protocol). 
Atmospheric CO2 levels increased immediately and significantly when Phl p 5 sensitized mice 
were nebulized with Phl p 5, but remained unchanged after challenges with OVA (Fig. 2 a), 
indicating endured and enforced respiration in allergen-, but not in  nonspecific airway 
provocation. O2 levels dropped in calorimetric cages of both groups immediately after aerosol 
challenges, indicating increased O2 consumption in the acute phase probably due to faster and 
deeper breathing. However, in the late phase (48 hrs after challenge), gas exchange continued 
to be increased in the Phl p 5 challenged mouse group. At the 48 hr timepoint, O2 
consumption was still significantly enhanced after specific challenges with Phl p 5 but not 
with OVA (Fig. 2 b) indicating that animals provoked with a nonspecific irritant recovered 
faster from alteration in gas exchange.  
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Alteration in gas exchange after challenge with specific allergen and irrelevant antigen 
results in a significant reduction of motor activity  
The physical activity pattern of mice was recorded before and after aerosolizations by 
counting the rearings (Z-axis movements) at three different timepoints; before, immediately 
after challenge and 48 hrs later. Rearing of mice could be assessed simultaneously with 
respiratory gas exchange measurements by the use of an infrared beam attached to the 
calorimetric cages. Regardless of the allergen/antigen used for provocation of the airways, 
physical activity was in both mouse groups drastically reduced (Fig. 2 c). Importantly, at the 
48 hr timepoint, activity continued to be significantly reduced, irrespective of the agent used. 
 
Blood gas analysis of Phl p 5-challenged allergic mice indicates impaired lung function 
combined with a metabolic disorder 
The results of the gas exchange measurements had indicated that airway challenge with Phl p 
5 led to profoundly increased consumption of O2 and production of CO2 in the asthma attack. 
Consequently, arterial blood samples from mice before sensitization and aerosol challenges 
(with either Phl p 5 or OVA) and right after were subjected to blood gas analysis (Fig. 3). 
Both challenged mouse groups showed a significant drop in pH (Fig. 3 a), pointing towards 
acidosis. Blood pCO2 remained relatively unchanged (Fig. 3 c), whereas cHCO3- was 
significantly reduced in Phl p 5-specific, but nonsignificantly in OVA challenged mice (Fig. 3 
b). Control mice which were sensitized and challenged with PBS and mice which were 
sensitized with Phl p 5 but challenged with PBS did not show variations of these parameters 
(data not shown). Taken together, these results indicate a higher rate of decompensation in the 
allergen-challenged mouse group.  
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Peripheral erythrocyte numbers substantially decline after specific and nonspecific 
aerosol challenges in hypersensitive mice  
Besides their function in O2/CO2 transport, erythrocytes bind and produce HCO3-, thus 
representing important buffer systems in the blood. Being effectively recirculated, they 
balance therefore pH extremes. When evaluating peripheral red blood cell counts (RBC), 
hemoglobin (HGB) and hematocrit (HTC) before and after aerosol challenge, we observed 
significant decreases of these parameters in the allergen-challenged groups, suggestive for 
increased localization of erythrocytes in the lung (Fig. 4). 
 
Allergen-triggered acute asthma but not nonspecific respiratory challenge is associated 
with increased airway inflammation  
Systemic sensitization combined with nebulization with Phl p 5 renders acute allergic asthma 
characterized by airway inflammation and mucus hypersecretion (Wallmann et al., 2010). 
Here, we determined to what extent aerosol challenge of Phl p 5-allergic mice with an 
irrelevant antigen, i.e. control antigen OVA, would induce airway inflammation as compared 
to the original allergen. For this purpose, systematic uniform random samples (SURS) were 
collected from the entire lung and analyzed for goblet cell metaplasia, mucus production, 
lymphoid follicles and infiltration of the airways with eosinophils 64 hrs after aerosol 
challenge (Fig. 5). In contrast to mice challenged with the allergen Phl p 5, mice immunized 
with Phl p 5 but challenged with OVA exhibited hardly any goblet cell metaplasia (Fig. 5 a) 
or mucus production (Fig. 5 b and c-e).  
When we assessed white blood cell counts (WBC) in arterial blood of Phl p 5-asthmatic mice, 
peripheral leukocyte numbers were substantially decreased in the allergen-exposed group but 
remained more or less unchanged in the group nebulized with control antigen OVA (Fig. 6 a). 
On the contrary, leukocytes seemed to infiltrate the airways where significant numbers of 
lymphoid follicles were found when mice were challenged with the specific allergen, slightly 
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less upon OVA challenge (Fig. 6 b and d-f). To determine whether these infiltrates are 
associated with eosinophilic immigration, we determined the percentage of those FOVs (field 
of views) exhibiting airway walls containing eosinophils. Eosinophilic infiltration was 
significantly increased in both, OVA and Phl p 5 challenged allergic mouse groups compared 
to naive controls (Fig. 6 c).  
 
Allergic mice aerosolized with the specific allergen exhibited higher Th2 cytokine 
mRNA production in splenocytes and lungs. 
To understand the events leading to the profound physiological and immunological 
differences between allergen- and nonspecific challenge, we next analyzed the expression of 
Th2 associated cytokines. As a measure for systemic immune deviation, spleen cells were 
investigated and compared to local effects in lungs.
 
The spleens and the left lung of each 
mouse were isolated 64 hrs after the last treatment. Relative expression of IL-4, IL-5 and IL-
13 mRNA levels was quantified by qRT-PCR. 
           Aerosol challenges of Phl p 5-allergic mice with OVA did neither considerably elevate Th2 
cytokine mRNA in spleens nor lungs as compared to completely naive animals. As expected, 
challenges with the specific allergen Phl p 5 elevated Th2 cytokine mRNA production in 
lungs and even more significantly in spleens (Fig. 7, a, b and c). These data indicate that 
significant transcription of IL-4, IL-5 and IL-13 is turned on as a consequence of specific 
allergen challenge and that it is a systemic event. 
 
 
Chapter II
42
J. Wallmann et al. 
 
DISCUSSION 
In allergy research, innovative mouse models and methods of acute allergic asthma are 
urgently needed for proof of  concept studies (Mojtabavi et al., 2002). Using major grass 
pollen allergen Phl p 5 as a model allergen, we have recently tested the treatment efficacy of a 
peptide mimotope vaccine with respect to airway inflammation and cytokine secretion in a 
memory model of asthma (Wallmann et al.,2010).  
In addition to the former approach, the present study was designed to actually evaluate the 
pathophysiological changes in acute allergic asthma of mice. In addition, we introduced a 
mouse group being aerosol challenged with an irrelevant antigen to define the cutting edge 
between pathophysiological changes in allergen-specific asthma versus nonspecific airway 
provocation. Today, a number of invasive as well as non-invasive tests are available for the 
experimental determination of lung function (Drazen et al., 1999). For the acute mouse 
model, we took here for the first time advantage of a highly sensitive open-circuit indirect 
calorimetric system able to record, besides parameters like food and drink intake, activity and 
respiratory metabolism (Dominguez et al., 2009).  
After development of acute allergic asthma of Phl p 5 hypersensitive mice due to aerosol 
challenges with the specific allergen, O2 and CO2 levels in the ambient air were monitored.  
Independent whether specific allergen or irrelevant antigen was used for the provocation, the 
O2 levels in the ambient air decreased significantly, indicating enhanced oxygen consumption. 
48 hrs after challenge, the allergen-challenged animals had not recovered yet. Simultaneously, 
CO2 levels in the air increased significantly in the allergen-exposed group only, indicating 
enhanced expiration in the acute phase, possibly an attempt for compensating the observed 
acidosis. Multiple potential causes of the acidosis are discussed, among them lactic 
production by respiratory muscles or tissue hypoxia during respiratory distress, at least in 
humans (Mountain et al., 1990). We failed to determine lactic acid in the samples, even 
though the pH values in the blood had dropped significantly. Further, significantly decreased 
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bicarbonate levels combined with slightly reduced pCO2 levels were recorded in arterial 
blood upon specific challenges with Phl p 5, reminding to human reports on metabolic 
acidosis in severe asthma (Meert et al., 2007, Mountain et al., 1990, Roncoroni et al., 1976) . 
This level of severity is not reached in our model, but on the other hand it has not been 
investigated so far which intensity of asthma in humans would lead to metabolic effects 
(Rashid et al., 2008). Interestingly, metabolic acidosis was recently associated with a 
bronchodilatory effect and thus may resolve bronchial obstruction (Brijker et al., 2009). 
Surprisingly, a substantial decrease of red blood cells, hematocrit and hemoglobin levels right 
after allergen challenges of the airways, with twofold significance upon specific airway 
provocation with Phl p 5 was observed. To the best of our knowledge, no reports on effects of 
asthma on red blood cells have been made so far, but sporadic evidence suggests that human 
asthmatics may experience a decrease of hematocrit during recovery from acute episodes 
(Gopalan et al., 1983). In mouse models of allergic asthma, the degree of overall airway 
inflammation, the cellular composition and location of infiltrates very much depends on the 
experimental disease induction protocol used (Epstein, 2006). In the memory model of acute 
asthma analyzed here, immunization and aerosol challenges with Phl p 5 rendered an overall 
modest induction of mucus production, lymphoid follicle formation and eosinophilic 
infiltration in the airways. The simultaneous drop of white blood cells in the periphery may 
illustrate the dynamics of leukocytes immigrating into the lung. Most prominent inflammation 
was observed in the proximal parts of the lung, perfectly representing the phenotype of acute 
asthma.  
Nebulization with an irrelevant antigen rendered milder overall lung inflammation, 
characterized by less and smaller lymphoid infiltration than following a challenge with the 
specific allergen. Eosinophilic infiltration of the airways occurred to a similar extent as in the 
allergen challenged mouse group.  
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In the sensitization process with an allergen, a number of different Th2-associated cytokines 
are implicated. Among them, IL-4 plays a pivotal role in the production of cytophilic IgE 
antibodies, which, upon crosslinkage by the corresponding allergen, induce the release of 
proinflammatory compounds leading to acute airway obstruction. In concert with IL-13, IL-4 
narrows airways by causing epithelial cells to swell and increases the contractibility of airway 
smooth muscle cells, thereby playing an essential role in AHR (Corry et al., 1996, Galli et al., 
2008). IL-5 is primarily engaged in the recruitment of eosinophils, with a possible role in 
airway injury acting possibly pro-inflammatory, or, in contrast, supporting airway remodeling 
(Bochner et al., 2005). Thus, the role of eosinophils in the clinical manifestion of asthma such 
as AHR has been questioned recently (Leckie et al., 2000, Radinger et al., 2009, Tournoy et 
al., 2000). IL-13 is involved in IgE isotype switching, but also in the effector phase of asthma 
by supporting goblet cell metaplasia and mucus production (Mitchell et al., 2010). 
As expected, IL-4, IL-5 and IL-13 mRNA levels from splenocytes of mice being sensitized 
and challenged with Phl p 5 were significantly increased in comparison to Phl p 5 sensitized, 
but OVA challenged mice. Interestingly, qRT-PCR measurements of the lungs indicated that 
similar to the systemic events, locally a significant elevation of IL-4 and an upward trend of 
IL-5 and IL-13 levels occurred.  
In summary, we demonstrate that respiratory exposition of grass pollen allergic mice with the 
specific allergen induces acute enforced respiration characterized by increased O2 
consumption and CO2 expiration, combined with metabolic acidosis, decreased motor activity 
and persistent local Th2-related airway inflammation. The impairment of respiration and 
tissue inflammation was profound and mice had not recovered 48 hrs after allergen challenge. 
In contrast, challenges with irrelevant antigen produced increased respiration which was, 
however, less pronounced and could be easier compensated. Further, also Th2-type lung 
inflammation was less pronounced upon nonspecific aerosol challenge. In both cases, we 
found significant impact of the provocation on the re-distribution of white and red blood cells 
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from the periphery to the lung. Future studies will address whether these phenomena are also 
relevant in human asthma patients.  
Taken together, our study clearly demonstrates that acute allergen-induced asthma versus 
provocation with a nonspecific trigger can be monitored and precisely categorized by the use 
indirect calorimetry in metabolic studies. We suggest that this novel application may also 
open new avenues towards understanding the events which are specifically and 
nonspecifically affecting the quality of life of asthma patients.  
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FIGURES 
 
 
Figure 1. Schematic protocol flow chart for induction and metabolic monitoring of grass 
pollen-induced acute asthma in mice. Airway inflammation was induced in BALB/c (n=20) 
sensitized with 10 µg Phl p 5 (days 0 and 21) and airway challenged twice on two consecutive 
days (day 31 and 32) with Phl p 5 or OVA. Nebulization of mice was performed twice a day 
with a four hours interval on two consecutive days in a plastic chamber connected to an 
ultrasonic nebulizer. Atmospheric O2 and CO2 levels within metabolic cages housing the 
nebulized mice were assessed (before, immediately after and 48 hrs after aerosol challenges). 
Mice were sacrificed (day 35) for tissue harvest. Sensitization and aerosol challenges are 
indicated with black arrows. Time points of metabolic cage measurements are highlighted in 
grey. Numbers below the x-axis represent days. 
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Figure 2. Nebulization of Phl p 5-allergic mice with the allergen, but not with an 
irrelevant antigen induces acute hyperventilation and decreased motor activity. BALB/c 
mice were sensitized by two i.p. injections with rPhl p 5a and ten days later nebulized with 
either aerosolized rPhl p 5a (n=10) or OVA in PBS (n=10). Respiratory gas analysis of mice 
was performed after they were put in metabolic cages, each cage housing one animal. 
Measurements were done before, right after and 48 hrs after the challenge nebulization. 
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Atmospheric CO2 (a) and O2 (b) concentrations within metabolic cages housing Phl p 5-
allergic, unchallenged mice were set 100% and the values after airway challenges were 
compared hereto. Simultaneously, mice were analyzed for their motor activity, whereby 
rearing of each mouse was recorded by an integrated laser (c). Data points of Phl p 5-
sensitized mice being subsequently challenged with OVA are represented in black, data points 
of mice immunized and aerosolized with Phl p 5 in red. Timepoints of measurements are 
indicated below the x-axis. Data are mean ± SD. n = 5 mice/group. Two independent 
experiments were performed. *, P < 0.05 and **, P < 0.01 for challenged versus unchallenged 
mice. 
 
 
 
Figure 3. Induction of acute Phl p 5-specific asthma causes an acid-base imbalance in 
mice. Mice were sensitized with Phl p 5 and subsequently aerosol challenged with either Phl 
p 5 or OVA. Arterial blood samples, taken from the tail artery of mice before sensitization 
and after airway challenges were subjected to blood gas analysis.  
pH (a) bicarbonate (b) pCO2 (c) and pO2 (d) levels in arterial mouse blood before 
sensitization and immediately after aerosol challenges (timepoints are indicated below the x-
axis). Black data points represent the mouse group sensitized with Phl p 5 but challenged with 
OVA, the red squares represent the mouse group sensitized and aerosol challenged with Phl p 
5. Data are mean ± SD. n = 5 mice/group. Two independent experiments were performed. *, P 
< 0.05 and **, P < 0.01 for challenged versus naive mice. 
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Figure 4. Specific and nonspecific airway provocation of allergic mice impact red blood 
cells. Mice were sensitized with Phl p 5 and subsequently aerosol challenged with either Phl p 
5 or OVA. Arterial blood samples, taken from the tail artery of mice before sensitization and 
after airway challenges were subjected to differential blood cell counting. RBC (a), HGB (b) 
and HCT (c) levels of naive, unsensitized mice and after they were sensitized and nebulized 
are shown. Black points represent the mouse group when sensitized with Phl p 5 but aerosol 
challenged with OVA, the red squares refer to mice challenged with Phl p 5. Data are mean ± 
SD. n = 5 mice/group. Two independent experiments were performed. *, P < 0.05 and **, P < 
0.01 for challenged versus naive mice. 
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Figure 5. Airway inflammation is induced upon challenge with the specific allergen, and 
less by the nonspecific antigen. Mice were sensitized with Phl p 5 and aerosol challenged 
with Phl p 5 or OVA. Three days later mice were anesthetized, lungs were fixated by tracheal 
installation and vascular perfusion was performed. Paraffin-embedded lungs were sectioned 
(2 µm) and stained with Periodic Acid Schiff for detection of mucus and mucus-secreting 
goblet cells (a and b). The volume of PAS-stained epithelial mucus and the area of epithelial 
basal membrane covered by goblet cells was determined as per total surface area of airway 
epithelial basal membrane. Representative lung histology from Phl p 5 sensitized and OVA 
challenged (c), Phl p 5 sensitized and Phl p 5 challenged (d) and naive, unsensitized mice (e).  
Data are mean ± SD. n = 5 mice/group. Two independent experiments were performed. *, P < 
0.05 and **, P < 0.01 for challenged versus naive mice. 
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Figure 6. Aerosol allergen challenge specifically attracts leukocytes to lungs. White blood 
cells were assessed from arterial blood of naive mice and after they were airway challenged. 
Differential blood cell counts were analyzed from blood of the tail artery of naive mice and 
after i.p. immunization with Phl p 5 and subsequent nebulization with OVA or Phl p 5 (a). 
Black points represent the mouse group sensitized with Phl p 5 but aerosol challenged with 
OVA, the red squares refer to mice challenged with Phl p 5. Mice were anesthetized on day 
36 after the final nebulization and lungs were fixed by tracheal installation. Paraffin-
embedded lungs were sectioned (2 µm) and stained with congo-red for eosinophils and 
hematoxylin and eosin (H&E) for lymphoid follicles. The volume of lymphoid follicles per 
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unit surface area of airway epithelial basal membrane was assessed (b). Eosinophilic 
infiltration of the airways was semi-quantitatively estimated as percentage of SURS sampled 
fields of view containing >2 eosinophils in the airway wall (c). The sensitization modality is 
indicated below the x-axis. Naive mice served as negative controls. Lung histology 
representatives with respect to lymphoid follicles from Phl p 5 sensitized and OVA 
challenged (d), Phl p 5 sensitized and Phl p 5 challenged (e) and naive, unsensitized  mice (f). 
Data are mean ± SD. n = 5 mice/group. Two independent experiments were performed. *, P < 
0.05 and **, P < 0.01 for challenged versus naive mice. 
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Figure 7. Nebulization of allergic mice with the allergen increases local and systemic Th2 
cytokine levels. Mice were sensitized and subsequently aerosol challenged with either the 
specific allergen or an unspecific control antigen. After the final airway challenges, mice were 
sacrificed and the spleen and left lung lobe of each mouse were isolated. Organs from naive 
mice served as negative controls. RNA from spleens and lungs were extracted, reverse 
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transcribed and the cDNA was used for amplification by qRT-PCR. Pooled cDNA of naive 
tissue was used as a calibrator and set the value 1; expression levels of the other samples were 
compared hereto. Th2 associated cytokine mRNA from splenocytes of Phl p 5-allergic mice 
after Phl p 5 or OVA nebulization was assessed. IL-4 (a), IL-5 (b) and IL-13 (c) mRNA levels 
from spleens (left) and lungs (right) of challenged mice. Naive organs served as negative 
controls. The sensitization modality is indicated below the x-axis. Data are mean ± SD. n = 5 
mice/group. Two independent experiments were performed. *, P < 0.05 and **, P < 0.01 for 
challenged versus naive mice. 
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Summary
Background One of the concerns of allergen-specific immunotherapy is the possible boost of
inflammatory allergen-specific T lymphocytes. To address this problem, treatment with B cell
epitopes devoid of allergen-specific T cell epitopes would be a promising alternative.
Objective In this study, we examined the therapeutic potency of a single mimotope, mimicking
a structural IgE epitope of grass pollen allergen Phl p 5 in an established memory mouse
model of acute allergic asthma.
Methods In the experimental set-up, BALB/c mice were primed with intraperitoneal injections
of recombinant Phl p 5a (rPhl p 5a) and subsequently aerosol challenged with the nebulized
allergen. Mice developed signs of bronchial asthma including hypereosinophilia around
bronchi, goblet cell hyperplasia and enhanced mucus production.
Results When the mice were subsequently treated with the grass pollen mimotope coupled to
keyhole limpet haemocyanin, bronchial eosinophilic inflammation and mucus hypersecretion
decreased. Further, a decrease of Th2 cytokines IL-4 and IL-5 could be observed in the
bronchoalveolar lavage (BAL). In contrast to rPhl p 5a, the mimotope was in vitro not able to
stimulate splenocytes to proliferation or IL-5 production. Despite not affecting the levels of
pre-existing IgE, vaccination with the single mimotope thus rendered anti-inflammatory
effects in a mouse model of acute asthma.
Conclusion From our data, we conclude that vaccination with a mimotope peptide
representing a single IgE epitope of the allergen Phl p 5a and being devoid of allergen-
specific T cell epitopes is able to down-regulate inflammation in acute asthma.
Keywords epitope-specific immunotherapy, grass pollen allergy, mimotopes
Submitted 2 March 2009; revised 11 September 2009; accepted 8 September 2009
Introduction
To date, specific immunotherapy (SIT) of allergy is the only
causative treatment with long-term effects in patients
suffering from IgE-mediated allergic disorders. The efficacy
of SIT is well documented [1]. It is ascribed to a down-
regulation or modulation of the allergen-specific Th2 re-
sponse and is accompanied by the induction of allergen-
specific blocking antibodies [2]. Furthermore, peripheral T
cell tolerance is turned on, initiated by the autocrine action
of IL-10 and TGF-b which are produced by antigen-specific
T cells in health and disease [2, 3].
On the other hand, clinical studies with T cell epitope
peptides have indicated that the directed stimulation of
allergen-specific regulatory T lymphocytes might be diffi-
cult due to the danger of recruitment of inflammatory T
cells [4, 5]. Therefore, treatments with B cell epitopes
devoid of T cell epitopes could be an attractive option. For
this, mimotopes, i.e. small peptides able to imitate struc-
tural B cell epitopes by molecular mimicry, could be useful.
Indeed, in a recent study, a mimotope cDNA construct has
been successfully shown to trigger allergen-specific anti-
body responses without the activation of allergen-specific
T cells [6]. To ensure sufficient immunogenicity of pure B
cell epitopes, T cell bystander help is needed and can be
provided by the carrier of the peptides [7]. Keyhole limpet
haemocyanin (KLH) is an attractive carrier as it allows the
dense and rigid display of coupled peptides.
With respect to grass pollen allergens, we have been
focusing on major timothy grass allergen Phl p 5a in
Clinical & Experimental Allergy, 1–9 doi: 10.1111/j.1365-2222.2009.03392.x
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previous studies and identified mimotopes from different
types of phage libraries [8, 9]. Three-dimensional analysis
showed structural, discontinuous surface patches of Phl p
5a as being relevant for IgE binding. The mimotopes were
able to interfere with the high-affinity interaction of IgE
with recombinant Phl p 5a (rPhl p 5a) ranging in the order
of 1011 M [8]. Consequently, the goal of the present study
was to examine for the first time the therapeutic efficacy
of a decameric peptide mimotope of Phl p 5a, termed here
Phl mim 5. In an established memory mouse model of
acute allergic asthma [10], we mimicked the human
sensitization process with Phl p 5 during the flowering
period via inhalative allergen challenges to induce an
asthmatic phenotype including inflammation and hyper-
secretion of mucus. To evaluate whether vaccination with
the Phl mim 5-peptide mimotope linked to KLH could
protect from acute asthma upon re-exposure to the aller-
gen, mice were, after vaccination therapy, re-challenged
with aerosolized allergen.
Materials and methods
Generation of peptide mimotopes
In a previous study, a phage clone encoding the peptide
mimotope C-KLGKFGAARV-C (1,12 cyclo), here termed
Phl mim 5, could be identified as a specific epitope mimic
(mimotope) of the IgE epitope of grass pollen major
allergen Phl p 5 [8]. This mimotope [molecular weight
(Mw): 1895.1 Da] was synthesized (piCHEM, Graz, Austria)
with a purity 495% and coupled to didecameric KLH
(Sigma-Aldrich, Sulzfeld, Germany), which has a Mw of
approximately 800 kDa with 50–75 potential binding
sites. The KLH used in this study is for preclinical purposes
and has no GMP quality like its monomeric counterpart
used for human clinical trials. The sequence GPGPGK-
(S-acetomercaptoacetic acid)-G was used as a linker.
Animals
BALB/c mice (female; 5–6 weeks) were purchased from
Charles River Laboratories GmbH (Sulzfeld, Germany) and
treated according to European Community rules of animal
care [11] with the permission of the Austrian Ministry of
Science (number BMBWK-66.009/0233-BrGT/2006).
Immunization of mice
Mice (n= 5) were immunized subcutaneously (s.c.) with Phl
mim 5-KLH [20mg/100mL phosphate-buffered saline (PBS);
piCHEM] on days 0, 7, 14 and 28. Control mice (n= 5) were
immunized s.c. with rPhl p 5a (10mg/100mL PBS) (Biomay,
Vienna, Austria) on days 0 and 21. Blood samples to be
analysed were taken after the last immunization.
For the asthma model, mice (n= 15) were immunized
intraperitoneally (i.p.) with rPhl p 5a (10 mg/100 mL PBS)
on days 0 and 21 or were sham treated with sterile PBS
(100 mL). Ten days later, mice were aerosol challenged
with nebulized rPhl p 5a (0.25mg rPhl p 5a/50mL PBS/
challenge) in a plexiglass chamber by an ultrasonic
nebulizer (Kendall, Aerodyne Omega, Oldenburg, Schles-
wig-Holstein, Germany) for 60min twice daily at a 4-h
interval on 2 consecutive days (days 31 and 32). At this
stage, physiologically relevant airway hyperreactivity was
proven by respiratory metabolism studies using the Oxylet
system (Panlab, Barcelona, Spain).
On days 48, 76, 84, 119, 126 and 150, mice (n= 5) were
immunized s.c. with either KLH (10 mg/100 mL PBS; Sig-
ma-Aldrich), Phl mim 5-KLH (20 mg/100 mL PBS; piCHEM)
or rPhl p 5a (2 mg/100 mL). During the entire treatment
period with the mimotope vaccine, no local or systemic
side-effects could be observed in the animals. Unsensi-
tized control mice (n= 5) were sham treated (100 mL PBS).
For disease relapse, mice were re-challenged with aero-
solized rPhl p 5a on day 172 following treatment (0.25mg
rPhl p 5a/50mL PBS per aerosol challenge).
Blood samples were drawn on days 0 (preimmune
serum), 22 (after systemic sensitization), 47 (after aerosol
challenge), 55, 84, 102, 126, 157 (during treatment) and
on day 172 (before sacrifice).
Specific serum immunoglobulin G1 antibody detection in
immunodot
Analysis of IgG1 from immunized mice was performed
in immunodot. Synthetic mimotope Phl mim 5 alone or
coupled to KLH, rPhl p 5a, rDer p 2 (kindly provided by
Prof. Dr J. M. Saint-Remy, University Leuven, Belgium) as a
control allergen and a control peptide (C-AISGGYPV-C
cyclo 1–12, a mimotope of profilin [12]) were dotted in
triplicates (1mg/dot) onto a nitrocellulosemembrane (Schlei-
cher & Schuell, Dassel, Niedersachsen, Germany). Dot strips
were air-dried and blocked with TBS/0.5% Tween-20 (TBST)
(Merck, Darmstadt, Germany)/5% dry milk powder (DMP)
overnight at 4 1C. Pooled mouse sera were diluted 1 : 10 in
0.5% TBST/1% DMP and incubated for 4 h at 4 1C. Bound
IgG1 was detected using IgG1-specific rat anti-mouse anti-
body (PharMingen, San Diego, CA, USA). The reaction was
developed using the ECL Plus Western Blotting Detection
System (Amersham, Buckinghamshire, UK).
Specific serum immunoglobulin G1 and E antibody
detection in enzyme-linked immunosorbent assay
For measurement of Phl p 5-specific IgE antibodies in an
ELISA, microtitre plates (Maxisorp, Nunc, Roskilde,
Denmark) were coated overnight at 4 1C with rPhl p 5a
(1 mg per well/100 mL 50mM NaHCO3, pH 9.6), washed with
TBST and blocked for 2 h at room temperature (RT) with
TBST/1% bovine serum albumin (BSA) (Sigma-Aldrich).
c 2009 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 1–9
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Sera were diluted 1 : 100 in TBST/0.1% BSA for IgG1 and
1 : 10 for IgE and incubated overnight at 4 1C. Plates were
washed and the respective isotype-specific rat anti-mouse
antibody (PharMingen) 1 : 500 in TBST/0.1% BSA was
added for 2 h at RT. After washing, plates were incubated
with horseradish peroxidase-conjugatedmouse anti-rat IgG
antibody (Jackson ImmunoResearch, West Grove, PA, USA)
diluted 1 : 1000 in 0.05% TBST/0.1% BSA for 2 h at RT.
Standard serial dilutions of the respective purified mouse
antibody (PharMingen) served as the standard. The reaction
was detected by adding 2,20-azino-bis-(3-ethylbenzthiazo-
line-6-sulphonic acid) diammonium salt (Sigma-Aldrich) in
citric acid and hydrogen peroxide. The optical density was
measured at 405–490nm in a microplate reader (Molecular
Devices, Mu¨nchen, Germany).
Recovery of the bronchoalveolar lavage and preparation of
cytospin slides
The tracheas of lethally anaesthesized mice (naı¨ve, asth-
matic or mimotope-treated) were cannulated (BD Venflon,
0.825mm; Heidelberg, Baden Wu¨rttemberg, Germany),
the supernatants were collected individually and cell
pellets were resuspended in 500 mL PBS (2104 cells) after
centrifugation at 800 g for 18min. Total leucocytes were
counted with a haemocytometer. Cytospin slides were
prepared and stained with May–Gru¨nwald–Giemsa [13]
to determine the cell differential. BAL supernatants were
individually collected for cytokine measurements.
Counts of inflammatory cells by Tissue FAXs technology
Following BAL recovery, tracheas were perfused with
formalin (4%). Paraffin-embedded lung sections of 4mm
were stained with Luna [14] for eosinophil and with periodic
acid-Schiff (PAS) for mucopolysaccharide staining. In each
mouse, the total eosinophil numbers surrounding 10
bronchioles positioned in a bordered area in parallel to the
central airways were counted by laser scanning micro-
scopy and analysed with the HistoQuest software module
(Tissuegnostics, Vienna, Austria). Visual grading of mucus
was performed in a blinded fashion in comparison with the
maximal release in asthmatic mice. This value was set to
100% and the other samples were compared hereto.
Cytokine measurements
IL-4, IL-5 and IFN-g measurements were performed by
ELISA with anti-mouse cytokine antibodies and standards
(Bender MedSystems, Vienna, Austria) in non-diluted BAL
samples according to the manufacturer’s instructions.
Isolation of splenocytes for the interleukin -5 cytokine
assay and the 3H thymidine proliferation assay
Mice (n= 5) sensitized and aerosol challenged with rPhl p
5a were killed and the spleens were removed. Spleen cell
suspensions of each mouse were prepared by cutting,
mincing and filtering the spleens through 70 mm nylon
meshes (BD Biosciences, Schwechat, Austria). Cells
were resuspended in RPMI medium (Gibco Invitrogen,
Lofer, Austria) supplemented with 10% fetal calf serum,
1% L-glutamine and 1% penicillin/streptomycin.
Mononuclear cells from each spleen were isolated by
density separation (Lympholyte-M; Cedarlane, Hornby,
ON, Canada) according to the manufacturer’s instructions.
Cells were plated (4105 cells/well) in triplicates in sterile
round-bottom 96-well tissue culture plates (Costar, New
York, NY, USA). For stimulation, rPhl p 5a, mimotope Phl
mim 5, control allergen Ara h 2 (from peanut; vector
kindly provided by Prof. Dr H. Sampson, Mount Sinai
School of Medicine, New York) and positive control Con A
(Sigma-Aldrich) (2.5 mg/mL each) were added. The cells
were cultured for 72 h at 37 1C and 5% CO2. The super-
natants were harvested and stored at 20 1C until further
Fig. 1. Antigenic cross-reactivity of mimotopes and recombinant aller-
gen Phl p 5a (rPhl p 5a) in immunodot. Pooled sera of mimotope- or of
rPhl p 5a-immunized BALB/c mice were tested for IgG1 antibodies
towards various antigens and control antigens (1 mg/dot) indicated on
the left-hand side. No reactivity could be detected to control allergen Der
p 2 from house dust mite and to control peptide Prof mim 1. Preimmune
sera represent the sera of naı¨ve mice. Bound IgG was detected with
peroxidase-labelled anti-mouse IgG. KLH, keyhole limpet haemocyanin.
c 2009 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 1–9
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use for cytokine determination. Single splenocytes were
pulsed with 0.5 mCi/well 3H thymidine diluted in 50 mL
RPMI medium for 16 h at 37 1C and 5% CO2. Cells were
harvested with a Filter Mate Harvester (Perkin Elmer,
Waltham, MA, USA) and radioactivity of DNA was mea-
sured in counts per minute and expressed as mean value
per mouse.
Measurement of IL-5 was performed by ELISA with anti-
mouse cytokine-antibodies and standards (Bender MedSys-
tems) in pooled supernatants of stimulated splenocytes
(diluted 1 : 2) according to the manufacturer’s instructions.
Statistical analysis
Statistical comparison between groups was performed by
the Mann–WhitneyU-test, using the software SPSS (version
14.0 for Windows). Differences were considered statistically
significant at Po0.05.
Results
Immunization with the mimotope induced Phl p 5-specific
immune responses in naı¨ve mice
For proof of the mimicry potential, naı¨ve mice were immu-
nized s.c. with the mimotope Phl mim 5 linked to KLH.
Testing of pooled sera showed that the mimotope-induced
IgG antibodies cross-reacted with the orthologue allergen Phl
p 5, but not with the control allergen Der p 2 or an unrelated
control mimotope of panallergen profilin, termed Prof mim 1
(Fig. 1). As expected, these sera showed IgG reactivity against
the carrier KLH, but also to uncoupled synthetic Phl mim 5.
Vice versa, rPhl p 5a immunization yielded predominantly
anti-Phl p 5 IgG and only slight crossreactivity towards Phl
mim 5, which may have to do with the fact that a mimotope
only represents a sub-epitope structure.
Immunoglobulin E antibody titres of asthmatic BALB/c
mice were not affected by mimotope and control treatments
For the induction of acute allergic asthma, mice were
sensitized i.p. with rPhl p 5a, followed by an aerosol
challenge. The allergen induced increases of specific IgE
in all sensitized mice (Fig. 2). Consecutively, groups of
mice were treated s.c. either with Phl mim 5 coupled to
KLH, with KLH alone or with rPhl p 5a, for control. During
the entire treatment period, the IgE (and IgG1, data not
shown) antibody titres of mimotope- and control-treated
mice remained elevated without a statistical difference
(Fig. 2).
Reduced eosinophil numbers in bronchoalveolar lavage
and peribronchiolar tissue of mimotope-treated mice
As serology did not reveal any differences between the
treated mouse groups, we aimed to analyse inflammatory
parameters in the lungs. BAL cytology revealed that
mimotope vaccination significantly prevented eosinophil
infiltration in the airways compared with mice treated
with KLH alone (P= 0.032) (Fig. 3). The effect was more
pronounced than treatments with the recombinant aller-
gen molecule rPhl p 5a (not significant).
Fig. 2. Recombinant Phl p 5a (rPhl p 5a)-specific IgE titres in sera of mice with grass pollen-specific asthma in ELISA. During treatments, IgE levels in all the
groups remained at comparable levels upon treatment with either allergen rPhl p 5a, the keyhole limpet haemocyanin (KLH)-linked mimotope Phl mim 5 or
KLH alone. Black arrows represent treatments, i.e. immunizations. White arrows indicate aerosol challenges of mice with the nebulized allergen. Values of
sham-treated control animals were below the detection limit.
c 2009 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 1–9
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Accordingly, we evaluated the eosinophil numbers in
peribronchiolar regions of the paraffin-embedded lungs by
Luna-staining highlighting the eosinophil granules in red.
The results indicate that Phl mim 5-KLH vaccination,
but not KLH treatment alone, protected mice from eosino-
philic infiltration (P = 0.029), similar to treatments with
rPhl p 5a (P= 0.024) (Figs 4a–c).
Mimotope treatments reduce T-helper type 2 cytokine
levels in bronchoalveolar lavage
The influence of the mimotope vaccine on the cytokines
IFN-g, IL-4 and IL-5 in BAL was investigated by ELISA. As
depicted in Fig. 5, treatment with Phl mim 5-KLH before
re-challenge with the allergen did not affect IFN-g pro-
duction (Fig. 5a), but slightly reduced IL-4 (P= 0.3) (Fig.
5b), although no significance could be achieved. With
respect to IL-5 levels in BAL, the effect of the mimotope
vaccine was comparable to treatment with rPhl p 5a, again
without a significant difference (P= 0.4) (Fig. 5c).
Mimotope treatments diminish mucus hypersecretion
within bronchioles
To determine whether mucus hypersecretion could be
modulated by mimotope vaccination, lung sections were
stained with PAS. Mucus production as a direct indicator for
goblet cell numbers was graded for each mouse group,
showing that Phl mim 5-KLH and rPhl p 5a but not KLH
vaccinations, induced a reduction of the goblet cell numbers
(Fig. 6a). Also, less mucus was visible in mice immunized
with the Phl mim 5-KLH and rPhl p 5a in comparison with
mice receiving KLH alone (Fig. 6b) or PBS (data not shown).
Fig. 4. Peribronchiolar eosinophil counts in mimotope-vaccinated mice. Mice were sensitized with recombinant Phl p 5a (rPhl p 5a) (1) and treated with
substances indicated on the x-axis. After treatment, they were aerosol re-challenged with rPhl p 5a (a). Peribronchiolar eosinophil counts were
determined and samples lying more than threefold away from the end of the box were defined as extremes and marked with asterisks (b). Representative
histological Luna stainings of lungs from mice treated with keyhole limpet haemocyanin (KLH) or Phl mim 5-KLH (c). Respective scattergram by Tissue
FAXs; x-axis: counted cells according to their size and the staining of their nuclei; y-axis: the number of eosinophils according to their granules stained
in red. PBS, phosphate-buffered saline.
Fig. 3. Mimotope treatments of BALB/c mice with grass pollen-specific
asthma are associated with a decreased number of eosinophils in bronch-
oalveolar lavage (BAL) cytospins. Mice were intraperitoneally and aerosol
sensitized with rPhl p 5a (1) and subsequently vaccinated with substances
indicated on the x-axis. Finally, mice were aerosol re-challenged with rPhl
p 5a. Calculation of eosinophils was performed by BAL cytometry. Po0.05.
BAL samples showing more than a threefold deviation from the end of the
box were defined as extremes and marked with asterisks.
c 2009 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 1–9
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Proliferation and interleukin-5 production of splenocytes
upon allergen or mimotope stimulation
To prove whether a mimotope, being devoid of allergen-
specific T cell epitopes, is able to activate allergen-specific
T cells, specific proliferation of splenocytes was analysed
in a 3H thymidine incorporation assay. Stimulation of
murine splenocytes with rPhl p 5a resulted in more
specific proliferation than treatment with mimotope Phl
mim 5 (P= 0.4) or irrelevant allergen Ara h 2 (P= 0.1) (Fig.
7a). In parallel, IL-5 production was monitored in pooled
supernatants of these stimulated splenocytes. In accor-
dance with the proliferation assay, more IL-5 production
could also be observed in the supernatants of rPhl p
5a-stimulated splenocytes, whereas there was hardly any
response to Phl mim 5 (Fig. 7b).
Discussion
In a previous study, decameric peptides have been defined
as IgE-epitope mimics (mimotopes) of major grass pollen
allergen rPhl p 5a [8]. The mimotope with the highest
specificity and binding capacity to rPhl p 5a-specific IgE
(termed here Phl mim 5) was chosen for synthesis and
coupling to KLH as an antigenic carrier in the present
study. Although previously less effective for immuniza-
tion, due to the low copy number of peptides when
displayed by phage protein pIII, we demonstrate here that
the same mimotope induced rPhl p 5a-reactive IgG in
naı¨ve BALB/c mice when displayed at a high density on
KLH. When manufacturing the KLH-mimotope conjugate,
we intended to approach an equimolar dose with rPhl p
5a. According to our calculation, the mimotope in this
Fig. 5. Th2 cytokines in the bronchoalveolar lavage (BAL) fluid of mimotope-treated asthmatic mice in ELISA. Mice were sensitized either with rPhl p 5a
(1) or treated with substances indicated below the x-axis. After aerosol re-challenge with rPhl p 5a, ELISA measurements revealed that the IL-4 (a) and
IL-5 (b) levels in BAL were reduced in Phl mim 5-treated mice, whereas the IFN-g (C) levels remained unchanged. PBS, phosphate-buffered saline; rPhl p
5a, recombinant Phl p 5a.
c 2009 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 1–9
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conjugate exceeded the molarity of rPhl p 5a per applied
dose by a factor of 5. Still, the levels of the mimotope-
induced IgG were lower and the immunodot showed that
it exhibited a higher degree of cross-reactivity with the
allergen than vice versa. Both findings may have to do
with the fact that the mimotope represents only a subunit
of the original allergen epitope.
As a continuation of our previous efforts, the present
study was designed to evaluate for the first time the
therapeutic capacity of Phl mim 5, taking advantage of
a memory mouse model of acute allergic asthma [15].
The induction of allergic asthma in mice is characterized
by airway hyperreactivity, eosinophilia, increased IgE
levels and mucus hypersecretion, which makes it a rele-
vant model of human allergic disease and useful for
testing novel therapeutics. In the BALB/c mouse model, a
sustained elevation of allergen-specific IgE can be in-
duced by rPhl p 5a sensitization; however, aerosol chal-
lenge with the grass pollen allergen is needed to induce
the asthmatic phenotype in the bronchi. To determine
whether immunological memory was generated, mice
were allowed to recover from acute disease before a re-
challenge, which should mimic re-exposure in the pollen
season. As intermittent exposure to seasonal allergens
already induces allergic symptoms, the rapid reaction to
these allergens in sensitized human patients or in mice
refers to immunological memory [10]. It has been demon-
strated previously that up to 800 days after the onset of
acute disease, mice were still susceptible to the develop-
ment of characteristic features of allergic asthma by a
secondary aerosol challenge using ovalbumin as a specific
antigen [15]. One predominant parameter of acute allergic
asthma in mice is the eosinophilic airway inflammation
that resolves within 11 days after onset of acute disease.
Indeed, we observed recurrent eosinophilic inflammation
in BAL fluids 48 h upon re-challenge with the allergen
rPhl p 5a. Even though representing a subunit vaccine as
outlined above, the mimotope vaccination inhibited peri-
bronchiolar eosinophilic infiltration and exsudation of
eosinophils into BAL, indicating the anti-inflammatory
capacity of this intervention. This effect seemed to be
antigen-specific, as treatments with the carrier KLH alone
had no effect.
IFN-g is described to promote cell-mediated immune
responses, and in case of asthma, inhibits the development
of airway hyperreactivity in the lungs induced by Th2
responses [16]. In our model, IFN-g levels in the BAL were
not changed; however, the Th2 cytokines IL-4 and IL-5
showed a downward trend in the mimotope-treated group,
pointing towards an immunomodulation. IL-4 plays a
major role in the induction of IgE, including the IgE
switch and airway hyperreactivity [17]. Similarly, IL-5
plays an important role in airway hyperresponsiveness
and is a central factor mediating eosinophil expansion,
priming, recruitment and prolonged tissue survival in
response to allergic stimuli [18]. IL-4 and IL-5 are thus
key regulators of airway inflammation and hyperreactiv-
ity in asthma. In our study, the relatively lower IL-5 levels
observed after mimotope therapy were in accordance with
lower counts of eosinophils. However, the somehow
reduced IL-4 levels in the mimotope-treated group did
not parallel IgE antibody titres, which remained un-
changed during the whole experiment. This may possibly
be due to long-lived plasma cells [19] and/or ‘tissue-
memory’ as receptor-bound IgE prolong the survival time
of effector cells in the periphery (reviewed in [20]). Under
healthy conditions, the columnar epithelial surface in the
bronchi comprises a small percentage of goblet cells and a
majority of ciliated cells, whereas in chronic airway
diseases like asthma, 20–25% of airway epithelial cells
transform mucus-producing goblet cells [21]. After an
acute onset of asthma, mucus within goblet cells of
allergic mice normally decreases to baseline levels within
30 days after acute disease. In contrast, upon repeated
allergen exposure, mucus production can be readily
restored and visualized on PAS-stained lungs sections.
The fact that mucus hypersecretion by goblet cells was
abrogated in the mimotope-treated animals supports our
Fig. 6. Mimotope-treated mice show diminished mucus secretion within
bronchioles. Mice sensitized with recombinant Phl p 5a (rPhl p 5a) (1) were
treated with the substances indicated. Following an aerosol re-challenge
with rPhl p 5a, mucus secretion in bronchioles was evaluated by periodic-
acid-Schiff staining. (a) Diagram showing the relative percentage of mucus
production in treated mice as compared with the level in untreated control,
which was set to 100%. (b) Representative lung stainings from mice treated
with keyhole limpet haemocyanin (KLH) or Phl mim 5-KLH (arrows:
mucus-positive cells). PBS, phosphate-buffered saline.
c 2009 Blackwell Publishing Ltd, Clinical & Experimental Allergy, 1–9
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hypothesis that B cell epitope mimics could have a
potency in abating allergic asthma. In this context, the
fact that the Phl mim 5 mimotope used here is devoid of T
cell epitopes may be advantageous [6] because allergen-
specific T lymphocytes cannot be re-activated through the
treatment. We believe that the absence of allergen-specific
T cell epitopes might have contributed to the observed
anti-inflammatory effects of the mimotope vaccine in our
mouse model. The duration of the vaccine effect remains
to be determined, but might be comparable to the effect of
other subunit vaccines. Another advantage is that mimo-
tope peptides can be easily produced synthetically on a
large scale and at relatively low costs.
Taken together, the results from this study suggest that
there are several arguments in favour of the presented
mimotope vaccine. It down-regulates bronchial inflam-
mation including Th2 cytokines, eosinophil counts and
mucus production without the activation of allergen-
specific T cells, and may thus relieve the symptoms of
grass pollen-induced asthma.
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A gene vaccine based on a mammalian expression vector containing the sequence of a peptide mimotope
of Phl p 5was constructed. To testwhethermimotope gene vaccines can induce allergen-speciﬁc antibody
responses via molecular mimicry, BALB/c mice were immunized using the mimotope construct with or
without a tetanus toxin T-helper epitope. Moreover, intradermal injection was compared to epidermal
application via gene gun immunization.
Immunization with both mimotope gene constructs elicited allergen-speciﬁc antibody responses. As
expected, gene gunbombardment induced a Th2-biased immune response, typically associatedwith IgG1
and IgE antibody production. In contrast, intradermal injection of the vaccine triggered IgG2a antibody
expression without any detectable IgE levels, thus biasing the immune response towards Th1. In an RBL
assay, mimotope-speciﬁc IgG antibodies were able to prevent cross-linking of allergen-speciﬁc IgE by Phl
p 5. A construct coding for the complete Phl p 5 induced T-cell activation, IFN- and IL-4 production. In
contrast, the mimotope-DNA construct being devoid of allergen-speciﬁc T-cell epitopes had no capacity
to activate allergen-speciﬁc T cells.
Taken together, our data show that it is feasible to induce blocking IgG antibodies with a mimotope-
DNAconstructwhen applied intradermally. Thus themimotope-DNA strategy has two advantages: (1) the
avoidance of IgE induction and (2) the avoidance of triggering allergen-speciﬁc T-lymphocytes. We there-
fore suggest that mimotope gene vaccines are potential candidates for epitope-speciﬁc immunotherapy
of type I allergy.
© 2009 Published by Elsevier B.V.
1. Introduction
Phage display libraries can be screened with allergen-speciﬁc
IgE antibodies to identify mimics of allergenic B-cell epitopes.
The selected mimics resemble IgE binding epitopes of the aller-
gen surface by virtue of their physico-chemical properties [1]. In
peptide form, such epitope-mimics (mimotopes) have repeatedly
been shown to induce epitope-speciﬁc, allergen-speciﬁc immune
responses [2–6]. Due to the fact that mimotopes do not contain
allergen-speciﬁc T-cell epitopes, the immune responses towards
mimotopes depend on the recruitment of bystander Th-cells. In
a previous study we could show that mimotopes per se were not
∗ Corresponding author. Tel.: +43 1 40400 5110; fax: +43 1 40400 5130.
E-mail address: erika.jensen-jarolim@meduniwien.ac.at (E. Jensen-Jarolim).
1 Both the authors contributed equally.
2 Present address: Division of Immunology, Infection and Inﬂammation, Univer-
sity of Glasgow, United Kingdom.
cross-reactive with the allergen at the T-cell level and that only
phage-displayed mimotopes could activate T-cells to generate a
mimotope-speciﬁcantibodyresponse [5]. Thisunspeciﬁcbystander
T-cell help can be provided by the phage coat protein pIII, which
is composed of 406 amino acids [7]. The mimotope-induced IgG
antibodies are then directed not only against the mimotopes, but
co-recognize the 3-dimensional allergen epitope via molecular
mimicry. Therefore, they are able to prevent the high-afﬁnity inter-
action between allergen and speciﬁc IgE antibodies [3,8] and thus
can be called blocking antibodies [9,10]. In several studies we and
others have already characterized peptides and anti-idiotypic Fab
fragments being mimotopes of different allergens and antigens
[2,6,11–13].
Besides attempts to improve protein-based allergen
immunotherapy by generation of allergen mutants, hypoallergens
or peptides, immunization experiments with allergen-encoding
DNA have yielded promising results. DNA vaccination does not
only prevent allergic sensitization, but is also capable to modulate
already ongoing Th2 responses [14–17]. Genetic immunization
0165-2478/$ – see front matter © 2009 Published by Elsevier B.V.
doi:10.1016/j.imlet.2008.12.002
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approaches with mimotope genes have hitherto been restricted
to tumor antigens [18]. Therefore, we investigated in the present
study whether this strategy could also be useful in the context
of allergy therapy. For this purpose, we designed the construct
“pCMV-F1”, a gene vaccine composed of a mimotope of the grass
pollen allergen Phl p 5 and phage coat protein pIII, the latter serving
as (i) a “non-allergenic” carrier protein, (ii) a source of T-helper
epitopes and (iii) a stabilizer of the three-dimensional exposure of
the mimotope. In a complementary strategy to further enhance the
immunogenicity of themimotope construct, a promiscuous tetanus
toxin T-helper epitope from Clostridium tetani [19] was additionally
introduced into a second construct, designated pCMV-F1/Tet.
As the route of the DNA application might critically affect the
cytokine milieu and thus the outcome of immunizations [20], we
aimed to compare head to head two different routes of gene vac-
cine administration. Whereas gene gun immunization using only
minute amounts of DNA has been demonstrated to trigger a pre-
dominant Th2 type immune response, intradermal application is
known to recruit efﬁciently Th1 cells, possibly also due to the deliv-
ery of higher amounts of DNA [21,22].
2. Materials and methods
2.1. Construction of the DNA immunization vectors pCMV-F1 and
pCMV-F1/Tet
In aprevious study, peptidemimotopeF1was identiﬁedas a spe-
ciﬁc epitope-mimic (mimotope) of grass pollen major allergen Phl
p 5 by screening a phage display librarywith Phl p 5-speciﬁc IgE [3].
The peptide library consisted of decameric peptides presented on
minor phage coat protein pIII of ﬁlamentous phage M13. Clone F1
(SRLGRSSAWV), showing the highest binding capacity to the anti-
bodies, was chosen for expression in the high copy number plasmid
pCI (Promega, Madison, WS, gb:CVU471199). The expression cas-
sette in pCI contains the CMV immediate-early promotor and can
provide three independent multiple cloning sites for the individual
in-frame cloning of, e.g. an ER-targeting leader sequence, the gene
of interest and a heterologous helper epitope [23]. For cloning of
pCMV-F1, a PCR reaction using the ﬁlamentous phage DNA (M13)
plus mimotope insert (F1) as a template was performed. To amplify
the sequence of the pIII phage coat protein togetherwith themimo-
tope sequence, the following primers were used, with F1-M13
DNA serving as a template: upstream primer pIII fwd1 EcoRI 5′-
CACCGAATTCATGGCTGAATGCAGTCGTCT-3′ and reverse primer pIII
rv1 XbaI 5′-GGGGTCTAGATTACTCATTTTCAGGGATAG-3′. The result-
ing 272bp (base pair) fragment was digested with EcoRI–XbaI and
ligated into the pCMV vector being digested with the same restric-
tion enzymes.
For the construction of the pCMV-F1/Tet vector (see Fig. 1),
inclusion of a foreign 63bp long toxin helper epitope (fnnftvs-
fwlrvpkvsashle), here named “Tet” from C. tetani was performed
[19]. A PCR reaction using the ﬁlamentous phage DNA (M13) as
a template was performed (upstream primer pIII fwd1 EcoRI 5′-
CACCGAATTCATGGCTGAATGCAGTCGTCT-3′ and the reverse primer
pIII rv2 MluI 5′-GGGGACGCGTCTCATTTTCAGGGATAGCAA-3′). The
resulting construct was digested with EcoRI–MluI and ligated into
a pCMV TPA Tet vector (constructed from pCI, see [23]) digested
with the same enzymes. For control, pCMV-mock, representing the
vector without phage coat protein pIII and insert, and pCMV-P5
encoding the recombinant Phl p 5a (rPhl p 5), were used [24]. Suc-
cessful cloning was controlled by sequencing all constructs in an
Abi PrismTM Genetic Analyzer (MWG Biotech, Germany).
The plasmids were propagated in E. coli strain XL-1 Blue and
large-scale puriﬁed with an Endo Free Plasmid Giga Kit (MWG
Biotech, Germany). Plasmid DNA was then analyzed for size by
Fig. 1. Map of the eukaryotic expression vector pCI. The universal expression vector
contains among other features a CMV immediate early promoter-enhancer region,
an optimized chimeric intron, a multiple cloning site (MCS) and the SV40 late
polyadenylation site. The inset shown here comprises the phage coat protein pIII,
the mimotope F1 and an additional tetanus toxin helper epitope (pCMV-F1/Tet).
agarose gel electrophoresis and quantiﬁed by spectrophotome-
try (OD260nm/OD280nm). Vectors were stored in endotoxin-free
water at −20 ◦C.
2.2. Animals
BALB/cmice (female; 6–10weeks)were purchased fromCharles
River Laboratories (Sulzfeld, Germany GmbH) and treated accord-
ing to European Community rules of animal care [25] with
the permission of the Austrian Ministry of Science (BMBWK-
66.012/0015-BrGT/2005 and BMWF-66.012/0015-CIGT/2007).
2.3. Mice and immunizations
The detailed immunization schemes are depicted in Fig. 2. Mice
(n=6) were immunized either by particle bombardment using a
Helios gene gun (Bio-Rad, Munich, Germany) or by intradermal
(i.d.) needle injection with pCMV-F1, pCMV-F1/Tet, pCMV-mock or
pCMV-P5 into the shaved abdomen. For gene gun immunizations,
plasmids were coated onto 1.6m gold particles and a helium dis-
charge pressure of 400psi was used to deliver a total of 4g per
immunization by two shots at two ventral sites. Particle bombard-
ment was performed on days 2, 16, 30 and ﬁnally four weeks later
at day 59 according to Scheiblhofer et al. [20]. Blood samples were
drawn on days 0, 15, 29, 44 and 73.
i.d. immunizations were performed using a slightly different
protocol, according to Hartl et al. [23] with 100g plasmid in a
volume of 200l PBS on days 2, 10, and 16 into 4–6 sites at the
shaved abdomen. Blood sampleswere taken on days 0, 9, 15 and 22.
According to an established immunization protocol [16], a control
group of mice was immunized subcutaneously (s.c.) with 5g rPhl
p 5 adsorbed to 100l Al(OH)3 in a total volume of 150l sterile
endotoxin-free PBS.
2.4. Serum immunoglobulin detection in ELISA
For the measurement of Phl p 5-speciﬁc IgG, 96-well high-bind,
ﬂat-bottomed immunoplates (FluoroNunc, Roskilde, Denmark)
were coated overnight at 4 ◦C with rPhl p 5 (0.1g per well/100l
PBS). Plates were washed with PBS/0.1% Tween 20 and blocked for
1h at room temperature with 200l/well PTB (PBS/0.1% Tween-
20/0.5% bovine serum albumin (BSA)).
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Fig. 2. Schemes of the immunization protocols. The axis indicates 14 days intervals. Gene gun (a) and intradermal immunization protocol (b) using the constructs pCMV-F1,
pCMV-F1/Tet, PCMV-mock and pCMV-P5. Subcutaneous application protocol (c) using rPhl p 5 as the immunization substance.
Sera were added at a dilution of 1:100 in 100l PTB for total
IgG, IgG1 and IgG2a and incubated for 1h at RT. Plates were washed
and incubated with horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG (BioRad, Germany), HRP-conjugated rabbit anti-
mouse IgG1 (Zymed, San Francisco, USA) or HRP-conjugated
rabbit anti-mouse IgG2a (Zymed), each diluted 1:1000 in PBT for
1h at RT.
The reaction was detected by adding Luminol (Boehringer-
Mannheim, Germany) 1:2 in aqua bidest. Chemiluminescence was
measured at 405–490nm by a LucyII ELISA-plate luminometer
(Anthos Labtec, Salzburg, Austria) and ﬂuorescence was calculated
in photon counts×1000 (kilo photon counts, KPC).
2.5. ˇ-Hexosaminidase release from rat basophil leukemia cells
RBL-2H3 cells were plated into 96-well, ﬂat-bottomed tissue
culture plates (Becton-Dickinson, Franklin Lakes, NJ, USA) at a den-
sity of 4×104 cells/well in 100l of RPMI 1640 supplemented
with 10% (v/v) heat-inactivated fetal calf serum, 100U penicillin
and streptomycin/ml, 4mM l-glutamine, 2mM sodium pyruvate,
10mM HEPES and 100M of 2-mercaptoethanol. Plates were incu-
bated o.n. at 37 ◦C, 95% relative humidity, 7.5% CO2.
Subsequently, 50l of supernatantwas removed. RBL cells were
passively sensitizedby addingpooled sera fromeitherDNA-s.c. rPhl
p 5-immunized mice or preimmune sera in a dilution of 1:100 for
2h at 37 ◦C.
RBL cells were washed twice with 200l/well Tyrode’s buffer
[23]. Cross-linking of FcRI-bound IgE was induced by addition of
rPhl p 5 (0.3g/ml in Tyrode’s buffer). For maximal release, 10l
10% Triton X-100 was added. Sera from untreated mice served as
negative control. Cells were incubated for 30min at conditions
indicated above. Thereafter, plates were centrifuged for 5min at
1200 rpm at RT, 50l of supernatants were transferred to fresh
plates and incubated with 50l 4-methyl-umbelliferyl-N-acetyl-
-d-glucosaminide (4-MUG) (Sigma, Deisenhofen, Germany) in
citrate buffer (0.1M, pH 4.5) for 1h at indicated conditions. The
reactionwas stopped by adding 100l glycine buffer (0.2M glycine
and 0.2M NaCl, pH 10.7) and ﬂuorescence was measured at
465–360nm using a microplate reader (Spectraﬂuor, Tecan, Aus-
tria). Results were calculated in relation to the percentage of total
-hexosaminidase released after addition of Triton X-100 (100%).
The release value obtained by Triton treatment was set 100% and
the other results compared hereto.
For the inhibition assay, RBL cells were passively sensitized with
sera of s.c. rPhl p 5-immunized mice in a dilution of 1:100 for
2h. Sera of mice to be tested for presence of blocking IgG anti-
bodies were pooled and heated at 56 ◦C for 1.5h to destroy the
-hexosaminidase being present in the serum. Subsequently, these
sera were incubated with 0.005g rPhl p 5 in dilutions 0, 1:50 and
1:20 for 2h prior to incubation with RBL cells.
2.6. Isolation of splenocytes and detection of cytokines
Mice were sacriﬁced and spleens were aseptically removed.
Spleens were minced in 1ml minimal essential culture medium
(MEM) and aggregated cells were sedimented for 10min. Lysis
of erythrocytes was performed with 5ml ACK (ammonium chlo-
ride lysis buffer): (150mM NH4Cl, 10mM KHCO3, 0.1mM Na2EDTA
dissolved in aqua bidest., pH 7.2–7.4) for 5min at RT. Cells were
resuspended in7mlMEMandcentrifuged for5minat300× g. After
repetition of the last step, cellswere plated into 96-well, ﬂat bottom
tissue culture plates (BD-Falcon, NJ, USA) (2×105 cells/well). For
stimulation, rPhl p 5 (20g/ml), ovalbumin (20g/ml) or medium
were added for 48h at 37 ◦C, 95% relative humidity, and 7% CO2.
IFN- and IL-4measurements of supernatantswere performed by a
Fluorescent Bead Immunoassay (BenderMedSystems, Vienna, Aus-
tria) of pure spleen supernatants according to the manufacturer’s
instructions.
2.7. Detection of cytokine producing cells by ELISPOT
Anti-IFN- (4g/ml) coated ELISPOT plates (Millipore, Bedford,
MA, USA) were washed with PBS and blocked with PBS/2% dry milk
powder (DMP) for 2h at RT.
At the day of sacriﬁce, spleens were harvested and cells were
cultured at a density of 2×105 cells/well with rPhl p 5 (20g/ml)
at 37 ◦C, 7% CO2 o.n. Plates were washed with PBS/0.1% Tween-20.
Biotinylated anti-IFN- antibodies (2g/ml in PBS/1%BSA)were
added and the plates were incubated at RT for 2.5h. Plates were
washed again and incubated with streptavidin-PE (1:1000 I PBS/1%
BSA) for 2h at RT. Cytokine-producing cells per 2×105 seeded cells
per well were detected by adding 3-amino-9-ethylcarbazole (AEC)
substrate according to the manufacturer’s instructions.
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Fig. 3. Phl p 5-speciﬁc IgG antibody responses after i.d. and gene gun immuniza-
tion. (A) i.d. immunization of DNA mimotope constructs pCMV-F1 and pCMV-F1/Tet
induced signiﬁcantly higher Phl p 5-speciﬁc IgG responses after the third immuniza-
tion (day 22) compared to injection of negative control pCMV-mock. Immunization
with pCMV-P5 served as positive control. (B) Gene gun immunization with both
DNA mimotope constructs after the fourth immunization (day 73) revealed 10-fold
higher IgG levels than i.d. administration.The induction of IgG was highly speciﬁc in
comparison to treatment with pCMV-mock. *P<0.05, **P<0.01.
2.8. Statistical analysis
Statistical comparison between groups was performed by the
Mann Whitney-U test, using the software SPSS (version 14.0 for
Windows). Differences were considered statistically signiﬁcant at
P-values <0.05.
3. Results
3.1. Mimotope-DNA induces allergen-speciﬁc immune responses
in i.d. and gene gun immunized BALB/c mice
To prove the mimicry potential of the mimotope constructs
pCMV-F1 and pCMV-F1/Tet, mice were immunized—either intra-
dermally (i.d.) or by biolistic gene transfer. Sera of mice immunized
with the mock vector, i.e. a construct lacking the mimotope as
well as the Tet gene (pCMV-mock), served as negative control.
Intradermal immunization with the gene of the entire Phl p
5-allergen (pCMV-P5) elicited a signiﬁcant increase of the allergen-
speciﬁc total IgG response already after two injections, as observed
from sera of day 15 (P<0.01). Three injections with both mimo-
tope constructs were needed to induce a signiﬁcant antibody
response (P<0.05), as analyzed in sera from day 22, although
with 100-fold lower titres than with the allergen-encoding con-
struct. Coexpression of the tetanus toxin helper epitope did
not increase the immunogenicity of the mimotope DNA vaccine
(Fig. 3A).
As depicted in Fig. 3B, four gene gun immunizations with the
mimotope constructs rendered a tenfold higher titre of Phl p 5-
speciﬁc IgG antibodies than i.d. treatment. However, a single shot
of the Phl p 5 DNA via gene gun (serum from day 15) was already
sufﬁcient to reach a signiﬁcantly elevated level of allergen-speciﬁc
IgG compared to all other groups.
3.2. Intradermal injection or epidermal gene gun application
differently polarize T-helper cell responses against the mimotopes
The inducedantibody responsewasanalyzed inmoredetailwith
regard to IgG1 and IgG2a levels (Fig. 4). Intradermal immunization
with the vector encoding the entire gene of Phl p 5, pCMV-P5 was
most effective in inducing Phl p 5-speciﬁc IgG1 and IgG2a (Fig. 4A)
as seen in sera taken at day 22. The mimotope-DNA constructs
pCMV-F1 and pCMV-F1/Tet induced comparable levels of anti-Phl
p 5 IgG1 and IgG2a (Fig. 4A) with the IgG1 titre being lower in the
pCMV-F1/Tet treated mice.
Four gene gun immunizations with all three constructs induced
signiﬁcantly higher IgG1 compared to IgG2a levels indicating a bias
towards a Th2 response (Fig. 4B). Mice immunized via gene gun
with pCMV-F1/Tet rendered signiﬁcantly higher IgG2a levels com-
pared to pCMV-F1.
Fig. 4. Phl p 5-speciﬁc IgG1 and IgG2a antibody subclass responses after vaccina-
tions. (A) Sera of mice from day 22 after three intradermal immunizations with all
three constructs (pCMV-F1/Tet, pCMV-F1, orpCMV-P5) rendered similar tiresof IgG1
and IgG2a antibodies. (B) Mice receiving four times particle bombardment by gene
gun showed higher IgG1 levels in all three DNA immunized groups (B). **P<0.01.
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Fig. 5. Functional IgE antibodies measured by RBL cell mediator release assay. (A)
rPhl p 5 protein, but none of the mimotope-DNA constructs pCMV-F1 and pCMV-
F1/Tet induced signiﬁcant Phl p 5-speciﬁc IgE synthesis after i.d. immunization. (B)
In contrast, gene gun injection triggered IgE induced -hexosaminidase release in
all experimental groups. Results are presented as relative percentage of total -
hexosaminidase released after addition of 10% Triton X-100. Samples showing more
than 3-fold deviation from the end of the box were deﬁned as extremes and marked
with numbers and circles. Numbers represent sample numbers in the order given
by the statistical program used. *P<0.05, **P<0.01.
3.3. Gene gun but not i.d. immunization with mimotope genes
triggers production of functional IgE
To investigate whether genetic immunization with mimotopes
induces IgE antibodies which can be cross-linked by the recom-
binant allergen, a rat basophilic leukemia cell release assay was
performed. RBL-2H3 cells were passively sensitized with sera
diluted 1:100 from mice immunized either i.d. or by particle bom-
bardment. Subsequent cross-linking was performed with rPhl p 5.
IgE-containing sera of mice immunized s.c. with rPhl p 5 served as
positive control [24], whereas. i.d. injection of both mimotope gene
vaccines or the entire gene of Phl p 5 did not induce detectable
IgE antibody levels (Fig. 5A). In contrast, gene gun immunization
induced functional, although variable IgE antibody levels in all
groups (Fig. 5B).
Fig. 6. Number of IFN- producing cells. Spleen cells of immunized mice were cul-
tured on ELISPOT plates coated with anti-IFN- antibodies and stimulated with rPhl
p 5. IFN- secreting cells could not be detected in the mimotope groups pCMV-F1
and pCMV-F1/Tet, neither after i.d. (A) nor after gene gun immunization (B). Only
i.d. immunization with the construct encoding the entire gene pCMV-P5 resulted in
IFN- production upon rPhl p 5-stimulation. In the gene gun treated group, only a
few IFN- expressing cells were detected, probably due to the Th2-biased immune
response after the immunization. Samples with signals showing more than 1.5-fold
interquartile range deviation from the end of the box were deﬁned as outliers and
marked as circles. Numbers represent sample numbers in the order given by the
statistical program used.
3.4. Allergen mimotope gene vaccines do not stimulate
allergen-speciﬁc T-cells
The capacity of theDNAconstructs to stimulate allergen-speciﬁc
T-cells was tested by measuring the production of IFN- and IL-4
from splenocytes of immunized mice. To determine the number of
IFN- producing spleen cells of the animals, an ELISPOT assay was
carried out. Neither i.d. nor gene gun immunizationwith themimo-
tope constructs resulted in T-cell stimulation and IFN- release
upon allergen stimulation. Signiﬁcantly increased numbers of IFN-
-producingcells (Fig. 6AandB), and increased levelsof IFN- in the
supernatants of stimulated splenocytes (Fig. 7A and B) were only
detected inmice immunizedwith the construct encoding the entire
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Fig. 7. IFN- levels in supernatants of stimulated spleen cells. Spleen cells of immu-
nizedmicewere stimulatedwith rPhl p 5 for 48h. IFN- secretionwas only observed
in spleen cell supernatants from the group immunizedwith the gene vaccine encod-
ing the allergen (pCMV-P5) after i.d. (A) and gene gun immunization (B). **P<0.01,
***P<0.001.
Phl p 5, which contained all relevant T-cell epitopes of the allergen
(P<0.001 to the i.d. group, P=0.002 to the gene gun group).
IL-4 production could also be detected in mice immunized with
the DNA encoding the recombinant allergen Phl p 5, treated by
gene gun bombardment. Levels of all other groups were below the
detection limit (Fig. 8).
3.5. Antibodies induced by allergen mimotope DNA act as
blocking antibodies
Due to their ability to bind allergen in a speciﬁc manner (as
demonstrated in Fig. 3), the anti-mimotope antibodies should be
able to block the binding of allergen to allergen-speciﬁc IgE onmast
cells or basophils. This was tested in an RBL-inhibition assay using
pooled sera from mice immunized intradermally with mimotope
Fig. 8. IL-4 levels in supernatants of stimulated spleen cells. Spleen cells of immu-
nized mice were stimulated with rPhl p 5 for 48h. IL-4 secretion was only induced
in the group immunized with the gene vaccine encoding the allergen (pCMV-P5)
after gene gun immunization. No IL-4 production was observed after intradermal
immunization with all of the constructs.
Fig. 9. Allergen-speciﬁc blocking antibodies. Antibodies with the potential to bind
rPhl p 5 and thus inhibit the cross-linking of sensitized mast cells were measured by
a -hexosaminidase release inhibition assay. Cell release was signiﬁcantly reduced
by preincubation of rPhl p 5 with anti-mimotope (raised i.d. with pCMV-F1) or anti-
Phl p 5 sera (raised i.d. with pCMV-P5) diluted 1:20 before addition to the sensitized
RBL cells. *P<0.05, **P<0.01.
gene vaccine pCMV-F1, a gene vaccine encoding the recombinant
allergen Phl p 5 (pCMV-P5), or preimmune sera. The results in Fig. 9
showthatpreincubationof allergenwithpooled seraofmice immu-
nized with Phl p 5 DNA or mimotope-DNA signiﬁcantly inhibited
(P<0.01 and P<0.05, respectively) the IgE cross-linking capability
of the allergen.
4. Discussion
Previously, we were able to deﬁne decameric peptides as IgE-
epitope mimics (mimotopes) of grass pollen allergen Phl p 5.
In these studies, the potential of protein-based mimotopes for
allergy immunotherapywas demonstrated by the induction of anti-
mimotope antibodies in BALB/c mice which were co-reactive with
Phl p 5 [3].
The similarity between mimotopes and B-cell epitopes con-
cerns the three-dimensional structure and the distribution of the
electrostatic charges, but mimotopes do rarely share sequential
homologies with the antigen they mimic [26]. In the context of
allergy treatment, this feature might be interesting, as a mimo-
tope vaccine could promote the stimulation and expansion of
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pre-existing allergen-speciﬁc B-cells, but simultaneously prevent
activation of allergen-speciﬁc T-cells. This might be advantageous
as it is known that allergen-speciﬁc T-cells may act proinﬂamma-
tory in late phase reactions [27]. Indeed, in the present study the in
vitro analysis of Th1 associated IFN- production and Th2 associ-
ated cytokine IL-4 from murine spleens conﬁrmed this hypothesis,
because immunization with mimotope gene vaccines did neither
stimulate proliferation nor cytokine production of allergen-speciﬁc
T-lymphocytes.
The safety concerns with respect to possible anaphylactic risks
for protein-based immunotherapies of allergy are an issue that
might be addressed by applyingmimotopes.Mimotopes induce IgG
antibodies which are B-cell epitope-speciﬁc [5], thereby avoiding
sensitization against neo-epitopes and an ampliﬁcation of the IgE
response during immunization. Moreover, the inhibition of the IgE
allergen interaction by virtue of their blocking capacity has been
shown [8,28]. On the other hand the potency of DNA vaccines to
counteract the IgE class switchby inducing IFN-producingCD4+ or
CD8+ T-cells has yieldedpromising results in theﬁeldof allergy [15].
Consequently, we attempted here to combine the speciﬁc features
of genetic immunization with the beneﬁcial effects of mimotopes.
Gene vaccines have been introduced into animal tissue by
several different routes, the most abundant being intradermal,
intramuscular or biolistic gene transfer. The latter has been sug-
gested to induce a Th1 milieu with 100–1000 times less amount of
DNA than intramuscular injection [29]. However, gene gun bom-
bardment was questioned for allergen immunotherapy by several
studies [22,30–33].
The aim of this study was to incorporate the sequence of a pre-
viously identiﬁed peptide mimotope of Phl p 5 into a eukaryotic
expression vector, the whole construct being designated pCMV-
F1. The introduced minigene encoding the mimotope peptide was
fused to the pIII phage molecule relevant for the display of mimo-
topes during their selection. This strategy intended to stabilize the
three-dimensional structure of the mimotope exactly in the way
it was selected during the biopanning procedure in context with
phageprotein pIII [34]. PIII could further act as a carrier protein sup-
porting T-cell bystander help, which has been postulated already
in the 1980s [35]. As the mimotope per se is composed of only 10
amino acids and has been shown so far only to induce immune
responses when coupled to a carrier [5], further T-cell help had to
be provided. The results actually demonstrated that the size of the
mimotope-pIII construct being 416 amino acids was sufﬁcient to
induce an immune response, which could not be further enhanced
by the addition of a promiscuous T-cell epitope from tetanus toxin.
Intradermal but not gene gun immunization with mimotope-DNA
induced blocking IgG antibodies without triggering IgE production,
which was demonstrated in a functional test, the RBL-assay. Gene
gun-mediated transfer delivers DNA more efﬁciently into cells by
depositingDNAcoatedbeadswithin the cytoplasm, thereby leading
to a higher transfection rate than does direct needle injection [36].
How this may impact IgE synthesis, remains to be answered. Our
data conﬁrm results questioning the applicability of gene gun bom-
bardment for allergen immunotherapy by several studies [20–22].
Thus, intradermal injection only eliciting IgG1 and IgG2a, but no
IgE antibodies, is the preferred route also for the mimotope gene
vaccine. The induced IgG antibodies also proved to have block-
ing activity by preventing allergen mediated cross-linking of IgE
bound via FcRI to effector cells. The type of the immune response
induced by different application routes thus gives an important
hint for future applications, e.g. administration of mimotope-DNA
in therapeutic settings.
Fromourdatawe conclude, that themimotopegene-vaccinehas
mimicry potential of amajor IgE epitope of the grass pollen allergen
Phl p 5. More importantly, the Th1-biased intradermal applica-
tion of the mimotope-DNA induced an efﬁcient immune response
comprising blocking IgG antibodies, simultaneously avoiding IgE
expansion and stimulation of allergen-speciﬁc T-cells. Based on
our data we suggest that the mimotope technology in context with
gene vaccination represents a promising novel option for epitope-
speciﬁc allergen immunotherapy.
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SUMMARY 
Allergen immunotherapy is today still associated with undesired side effects. This is in part 
due to the induction of anaphylactogenic antibodies directed against irrelevant molecules or 
even irrelevant epitopes within the applied allergens. This could be avoided by epitope-
specific immunotherapy using mimotope peptides or anti-idiotypic Fab fragments with 
mimicry potential (reviewed in Chapter I) instead of allergens. This thesis aimed to further 
optimize mimotope immunotherapy against grass pollen allergy, and to set up and perform the 
necessary proof of concept studies.  
Therefore, in the first experimental approach (Chapter II), a mouse model of allergic asthma 
was adapted to sensitization with grass pollen major allergen Phl p 5. Acute asthma was 
induced via systemic sensitization followed by inhalative allergen challenge rendering mucus 
secretion, lymphoid follicle formation and eosinophilic inflammation of the airways. To 
discriminate allergic asthma from non-specifically triggered airway hyperreactivity, we added 
ovalbumin (OVA) being an irrelevant control antigen for aerosolization of Phl p 5-allergic 
mice. In an innovative approach we performed respiratory gas exchange measurements by 
indirect calorimetry before and after challenges with aerosolized antigens. Enhanced 
respiration was found up to 48 hrs after provocation in the Phl p 5-nebulized mouse group 
only, characterized by significantly increased consumption of O2 and release of CO2 into 
exhaled air. Although airway inflammation of the OVA challenged group was overall milder 
than in mice with allergic asthma, both groups showed significantly less motor activity and 
exhibited acidosis combined with a sharp decline of white and red blood cells shown to be 
redistributed to the lung. This mouse asthma model therefore proved to be of 
pathophysiological relevance, being suitable not only for exploring the mechanisms of 
allergen- induced asthma versus non-specific airway provocation, but importantly also for 
proof of concept studies for mimotope vaccines. 
 
Summary
76
Consequently, Chapter III shows an approach using in such a way sensitized Phl p 5-
asthmatic mice for therapeutical vaccination with a synthetic peptide mimotope linked to 
carrier KLH. When mimotope-treated mice were then re-exposed with the aerosolized Phl p 5 
to mimic allergen re-exposure of humans in the pollen season, they exhibited significantly 
lower eosinophil numbers in the bronchoalveolar lavage and peribronchiolar tissue as well as 
an impressive downregulation of mucus production as compared to sham-treated animals or 
animals treated with KLH only.   
To further improve mimotope technology, we constructed in Chapter IV a minigene vaccine 
by translating the same peptide mimotope as used in the asthma model into a DNA vaccine. 
We compared head to head two different administration routes for immunization with the 
gene vaccine. Whereas gene gun bombardment was found to be associated with a Th2 biased 
immune response, intradermal injection did not induce IgE production but rendered blocking 
IgG antibodies able to inhibit allergen-mediated crosslinking of effector cell-bound IgE. In 
addition, no proliferation and cytokine production of allergen-specific T cells were observed.  
The pre-clinical evidence collected in this thesis work suggests that mimotopes in peptide or 
DNA form have therapeutic potency for the treatment of allergic diseases. This is possibly 
due to the fact that they represent pure B cell-epitope mimics and completely avoid the 
activation of any pro-inflammatory T-lymphocytes.  
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ZUSAMMENFASSUNG  
Die Immuntherapie mit Allergenen ist heute noch immer mit unerwünschten Nebenwirkungen 
assoziiert. Zum Teil ist dies bedingt durch die Induktion von anaphylaktogenen Antikörpern,  
die gegen irrelevante Moleküle oder gar irrelevante Epitope der eingesetzten Allergene 
gerichtet sind. Dies könnte durch epitopspezifische Immuntherapie verhindert werden, bei der 
Mimotope oder anti-idiotypische Antikörper mit Mimikry-Potential (Review in Chapter I) 
anstelle von Allergenen eingesetzt werden. Das Ziel dieser Doktorarbeit war es, die 
Mimotoptherapie gegen Gräserpollenallergie weiter zu optimieren und die hierfür 
notwendigen proof of concept Experimente zu etablieren und durchzuführen. 
Im ersten experimentellen Ansatz (Chapter II), wurde ein Mausmodell für allergisches 
Asthma für die Sensibilisierung mit dem Graspollen-Hauptallergen Phl p 5 adaptiert. Akutes 
Asthma wurde durch systemische Sensibilisierung, gefolgt von inhalativer Exposition mit 
dem Allergen induziert, wodurch Mukussekretion, Lymphfollikelbildung und eosinophile 
Entzündung der Atemwege ausgelöst wurden. Um zwischen allergischem Asthma und un-
spezifisch getriggerter Hyperreagibilität zu unterscheiden, fügten wir noch Ovalbumin (OVA) 
als ein irrelevantes Kontrollallergen für die Aerosolisierung von Phl p 5-allergischen Mäusen 
hinzu. In einem neuartigen Ansatz führten wir Analysen des Austausches der Atemgase 
mithilfe indirekter Kalorimetrie vor und nach Provokationen mit aerosolisierten Antigenen 
durch. Verstärkte Atmung konnte nach 48 Stunden nur in der mit Phl p 5 nebulisierten 
Mausgruppe festgestellt werden, charakterisiert durch erhöhte O2 Konsumation und CO2 
Freisetzung in die Ausatemluft. Obwohl die Atemwegsentzündung der mit OVA provozierten 
Gruppe generell schwächer als in Mäusen mit allergischem Asthma war, zeigten beide 
Gruppen eine signifikante Abnahme der motorischen Aktivität und wiesen Azidose 
kombiniert mit einem prägnanten Abfall von roten und weißen Blutkörperchen in der 
Peripherie auf, gepaart mit deren Umverteilung in die Lunge. Daher ist die 
pathophysiologische Relevanz dieses Mausmodells erwiesen. Es dient aus diesem Grund 
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nicht nur der Erforschung der Mechanismen von allergeninduziertem Asthma versus nicht-
spezifischer Atemwegsprovokation, sondern eignet sich auch für proof of concept Studien 
von Mimotopvakzinen.  
Folglich zeigt Chapter III einen Ansatz, bei dem solchermaßen sensibilisierte Phl p 5-
asthmatische Mäuse zur therapeutischen Vakzinierung mit einem synthetisch hergestellten 
Mimotop gekoppelt an KLH, eingesetzt wurden. Als Mimotop-behandelte Mäuse mit dem 
aerosolisierten Phl p 5 re-exponiert wurden um die Allergenexposition in der Pollensaison 
beim Menschen nachzuahmen, wiesen diese eine signifikant geringere Zahl an Eosinophilen 
in der Bronchoalveolarlavage und im peribronchiolaren Gewebe, sowie eine beeindruckende 
Herunterregulation der Mukusproduktion im Vergleich zu den „sham“-behandelten Tieren 
oder zu Mäusen, die nur mit KLH behandelt wurden, auf. 
Um die Mimotoptechnologie weiter zu verbessern, konstruierten wir in Chapter IV eine 
Minigen Vakzine, indem wir das im Asthmamodell verwendete Peptidmimotop in eine DNA 
Vakzine übersetzten. Wir verglichen parallel zwei verschiedene Verabreichungswege für die 
Immunisierung mit der Genvakzine. Die Applikation mit der Gene gun war mehr mit einer 
Th2 –ausgerichteten Immunantwort assoziiert. Im Gegensatz dazu wurde durch intradermale 
Injektion des Minigenkonstruktes keine IgE Antwort induziert, sondern die Produktion 
blockierender IgG Antikörper ausgelöst, welche das allergenvermittelte Crosslinking von 
Effektorzell-gebundenem IgE inhibieren konnten. Darüber hinaus konnte keine Proliferation 
und Zytokinproduktion von allergen-spezifischen T-Zellen beobachtet werden. 
Die präklinischen Befunde welche in dieser Doktorarbeit erhoben wurden deuten darauf hin, 
dass Mimotope in Peptid oder DNA Form therapeutisches Potential für die Behandlung von 
allergischen Erkrankungen, im besonderen Asthma, besitzen. Dies ist wahrscheinlich auf die 
Tatsache zurückzuführen, dass Mimotope ausschließlich Allergen- B-Zellepitope 
repräsentieren, jegliche Aktivierung pro-inflammatorischer T-Lymphozyten jedoch 
ausgeschlossen werden kann.  
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